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ABSTRACT 
 
The pharmacological basis for the use of the drug disulfiram for alcoholism is 
its inhibition of liver aldehyde dehydrogenase (ALDH2). Recent studies have 
reported that disulfiram exhibited an anti-craving effect with both alcohol 
addiction and cocaine dependence. Inhibition of ALDH2 cannot explain 
disulfiram’s efficacy in cocaine dependence. The disulfiram metabolite S-(N, 
N-diethylcarbamoyl) glutathione (carbamathione) is formed from disulfiram 
and appears in the brain after the administration of disulfiram. Carbamathione 
has no effect on liver ALDH2 and is a partial non-competitive inhibitor of the 
N-methyl-D-aspartic acid (NMDA) glutamate receptor. The effect of 
carbamathione on the neurotransmitter systems involved in craving and 
addiction is unknown. The aim of this research project was to develop 
analytical methods to determine carbamathione and relevant neurotransmitters 
in rat brain microdialysis samples in order to elucidate the pharmacokinetics 
and pharmacodynamics of carbamathione. The effect of disulfiram on the 
brain neurotransmitters was evaluated. The significance of this research is that 
carbamathione may be involved in the anti-craving effect observed with 
disulfiram, and thus may be used as a pharmacological tool to improve the 
effectiveness of disulfiram therapy in cocaine and alcohol addiction.     
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 1 
1 INTRODUCTION 
Alcohol and cocaine abuse are significant public health issues. Several effective 
pharmacotherapies for alcohol dependence have been identified, but the search for 
an effective therapeutic agent for cocaine dependence has proved difficult. It has 
been suggested that disulfiram offers a promising treatment option since it has 
shown efficacy in both alcohol and cocaine addiction. In this chapter, the 
epidemiology, pharmacology, and known pharmacotherapeutic agents for alcohol 
and cocaine addiction are discussed. In addition, some of the relevant clinical 
studies linking disulfiram with alcohol and cocaine addiction are also covered. 
Carbamathione, a metabolite of disulfiram, may play a role in disulfiram’s 
efficacy in alcohol and cocaine addiction since it appears to cross the blood-brain 
barrier (BBB) and may have an effect on various neurotransmitter systems in the 
brain. Microdialysis, a powerful in vivo tool that can be used to determine various 
substrates in discrete areas, was used to measure brain neurotransmitters. The 
principles of microdialysis and the analytical methods used to detect 
neurotransmitters in microdialysis samples are also discussed. 
 
 2 
1.1 Alcoholism 
1.1.1 Epidemiology 
Alcoholism is one of the most common neuropsychiatric diseases with a 
worldwide prevalence of 8.5%.1  Alcohol abuse is not only associated with 
deleterious effects on the physical and psychological health of individuals, but 
also has serious socioeconomic outcomes in the form of criminality, decreased 
productivity, and increased healthcare costs. In fact, it has been estimated that on 
a worldwide scale, over 6% of an industrialized nation’s gross domestic product is 
spent on costs related to alcohol and alcoholism.2 In addition, the percentage of 
total disability-adjusted life years (calculated by adding the years of life lost due 
to premature mortality and living with disability) of the world population caused 
by chronic alcohol use is as high as 4% (compared with 2.2% for AIDS).3 In an 
estimate of the factors responsible for the global burden of disease, alcohol 
contributes to 3.2% of all deaths worldwide.2 
 
1.1.2 Pharmacology 
Alcohol, or more specifically ethanol, is the most commonly used drug of abuse 
in the world. This is because it is so widely available, can be purchased easily and 
is not associated with the kind of social stigma related to other drugs of abuse.  
Ethanol is a relatively simple compound with the chemical formula C2H5OH. It is 
 3 
a clear liquid that is extremely soluble in water and fat tissue. When ingested, 
alcohol is completely and rapidly absorbed from the duodenum and to a small 
extent from the stomach into the blood and is distributed into the total body water. 
The metabolism of alcohol occurs primarily in the liver in a two step process as 
shown in figure 1.1. In the first step, alcohol is oxidized by the enzyme alcohol 
dehydrogenase to form acetaldehyde, which is metabolized very rapidly and 
usually does not accumulate. However, when large amounts of alcohol are 
consumed, accumulation of acetaldehyde may cause symptoms like headache, 
nausea and dizziness. In the second step of alcohol metabolism, acetaldehyde is 
metabolized by the mitochondrial low Km aldehyde dehydrogenase enzyme 
(ALDH2) to acetic acid and eventually to carbon dioxide and water.4 
 
1.1.3 Neurochemistry 
For many years, it was believed that the effects of alcohol were mediated through 
the non-specific disruption of neuronal lipid bi-layers. However, it is now 
accepted that alcohol acts by binding with and altering the function of specific 
receptor proteins, particularly membrane-bound ligand-gated ion channels and 
voltage-dependent ion channels.5 
 
 
 4 
Figure 1.1 Metabolism of ethanol. 
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1.1.3.1 Dopaminergic System  
It is widely accepted that dopamine neurotransmission within the 
mesocorticolimbic system plays a critical role in addiction. Dopamine neurons 
have cell bodies located in the ventral tegmental area (VTA) that send axonal 
projections to the prefrontal cortex (mesocortical) and the nucleus accumbens 
(mesolimbic). The dopaminergic brain reward system appears to play a 
fundamental role in the mechanisms of alcohol intake and craving. Alcohol 
consumption results in an increase in dopamine levels in the nucleus accumbens, 
which has been defined as the “reward center” of the brain.6,7 Earlier studies with 
self-administration of alcohol in alcohol-dependent rats showed that alcohol 
increased extracellular dopamine in the nucleus accumbens in a dose-dependent 
manner, and dopamine antagonists blocked alcohol self-administration in rats.8-10 
Also, the systemic administration of alcohol increased the release of dopamine as 
well as the rate of dopamine cell firing in brain regions involved in the reinforcing 
effects of alcohol.11 Furthermore, in animal studies, dopaminergic drugs affected 
alcohol self-administration.12 Neuroimaging studies in humans also revealed an 
alcohol-induced release of dopamine in the nucleus accumbens area of the central 
nervous system (CNS), and it was suggested that individuals who are vulnerable 
to developing alcohol dependence may have a lower central dopaminergic tone.13-
15 Even though many animal studies have suggested a strong relationship between 
dysfunction of the dopaminergic system and alcohol dependence, clinical studies 
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with drugs that affected the dopaminergic system have been inconsistent. For 
example, olanzapine, an antipsychotic, reduced the urge to drink after a drinking 
cue, but it had no effect on the rewarding effects of alcohol in social drinkers.16 
Earlier studies by Shaw et al. showed that the dopamine D2 receptor blocking 
agent tiapride reduced the severity of ethanol withdrawal, improved drinking 
outcomes, and reduced craving.17 However, amisulpride, a dopamine D2 receptor 
antagonist, had no effect on preventing relapse in alcoholics exhibiting ethanol 
dependence.18 Even though these clinical studies were inconclusive, evidence 
remains that the dopaminergic system may play an important role in the 
development of novel pharmacotherapeutics for alcohol addiction. 
 
1.1.3.2 GABAergic System 
Gamma-amino butyric acid (GABA) is the primary inhibitory neurotransmitter in 
the mammalian CNS, and activation of GABAA receptors by GABA tends to 
decrease neuronal excitability. GABAA receptors play a central role in both the 
short and long-term effects of alcohol in the CNS. When GABAA receptors are 
acutely exposed to alcohol, there is an increase in receptor activity and 
potentiating GABA-gated current, which is one of the reasons that alcohol is often 
thought of as a depressant. Chronic alcohol exposure results in a down-regulation 
of GABAA receptor function and may represent a mechanism for tolerance to 
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alcohol. This decrease in GABAergic function is thought to result in seizure 
susceptibility observed when chronic alcohol consumption ceases. Low levels of 
GABA may contribute to symptoms of alcohol withdrawal and associated 
neurotoxicity. In addition, the GABAA receptors play a role in mediating 
dopamine levels in the mesolimbic system. Long-term alcohol exposure decreases 
GABAA receptors, which in turn results in an increase in dopamine release in the 
VTA.5 During the withdrawal/negative affect stage of addiction, enhanced alcohol 
self-administration during acute withdrawal was reduced in a dose-dependent 
manner by the direct administration of a GABAA agonist into the central nucleus 
of the amygdala suggesting the involvement of the GABAergic system during 
acute alcohol withdrawal.19  The implication of the GABA system in the acute 
reinforcing effects of alcohol has led to the investigation and clinical trials of 
several GABAergic agents. Gabapentin, which has structural similarities to 
GABA, decreased alcohol withdrawal hyper-excitability in hippocampus slices, as 
well as convulsions in alcohol-withdrawn mice.20,21  
 
1.1.3.3 Glutamatergic System 
Glutamic acid (glutamate) is the major excitatory amino acid neurotransmitter in 
the CNS. Its excitatory effect on neurons is mediated by activating receptors, 
which are gated to ion channels or to a protein that mediates a second messenger. 
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One of the most powerful effects of alcohol is to reduce the pace of brain activity, 
in part by decreasing the excitatory actions of the neurotransmitter glutamate at 
the N-methyl-D-aspartic acid (NMDA) subtype of glutamate receptor. In several 
neurochemical studies, pharmacologically relevant concentrations (50 ± 10 
mmol/L) of alcohol were shown to inhibit or antagonize the action of agonists at 
the NMDA receptor.  Although acute alcohol administration disrupts 
glutamatergic neurotransmission by inhibiting the response of the NMDA 
receptors, chronic alcohol consumption results in the development of glutamate 
hypersensitivity by up-regulating NMDA receptor number and function. The up-
regulation of the NMDA receptor is thought to be a result of the physiological 
response to prolonged NMDA inhibition. Cessation of prolonged and chronic 
alcohol consumption causes a marked increase in glutamate activity at 
postsynaptic neurons and in extreme cases, glutamate-induced excitotoxicity.22,23 
Recent advances in the neurobiology of addiction and the developing knowledge 
base suggest that the dopaminergic and glutamatergic systems are inter-related 
(figure 1.2).24 Considering this circuit, the glutamatergic projection appears to be 
the final common pathway for the initiation of drug seeking behavior by a drug-
associated cue or the drug itself which increases dopamine release in the 
prefrontal cortex. In addition, the GABAergic and glutamatergic systems also 
appear to be inter-related (see figure 1.2).  
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Figure 1.2 Effect of alcohol on brain neurotransmitters.  
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Alcohol consumption facilitates GABAergic transmission by interaction with the 
GABAA receptor and inhibits glutamatergic function at the NMDA receptor. 
 
1.1.4 Pharmacotherapeutics 
No medication has been found to be effective in treating alcohol abuse and 
dependence. The only three medications used for the treatment of alcohol abuse 
that have been approved by the U.S. Food and Drug Administration (FDA) are 
disulfiram, naltrexone, and acamprosate. Disulfiram has been used since 1948 
when its action as a deterrent was first recognized by Hald and Jacobsen.25 
Naltrexone, previously used for opioid dependence was investigated, and in 
seminal studies, Volpicelli et al. and O’Malley et al. reported that naltrexone 
offered improvement in alcohol dependence. This led to its subsequent approval 
by the FDA.26,27 Acamprosate, which has been used in Europe since the 1990s, 
was approved by the FDA for ethanol dependence in 2004. The mechanism of 
action for acamprosate is still not fully understood. The degree of efficacy for 
each of these agents remains controversial. 
 
Drug discovery and development of new agents specific for ethanol abuse is 
almost non-existent. There are several reasons for this. One is that ethanol 
addiction is considered to be a chronic brain disease, progressing from social 
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drinking to withdrawal and dependence. It is a complex process and is not 
completely understood. Therefore, from a pharmacotherapeutic standpoint, it is 
not totally clear which stage of the addiction process should be targeted, which 
makes drug development difficult. Another and perhaps more important reason is 
that drug discovery and development and subsequent FDA approval is a time-
consuming and costly process. From bench to bedside, drug development takes at 
least 12 years and often longer, and developmental costs are in excess of $1 
billion. Drug discovery by the pharmaceutical industry has therefore focused on 
disease states that are perceived to have a better opportunity for return on 
investment: cancer pharmacotherapy; cardiovascular, gastrointestinal, 
neurological, and behavioral disorders; infectious diseases; and sexually related 
disorders. Thus the development of new chemical entities by the pharmaceutical 
industry that are specific for the treatment of ethanol abuse and substance abuse in 
general has a low priority. Because of the high cost of drug discovery, the 
discovery approach currently used to identify agents for ethanol abuse is to study 
agents that have already received FDA approval for other disorders and evaluate 
their potential as drug candidates. These include topiramate and gabapentin 
(which affect the GABA and glutamatergic pathways), ondansetron (a serotonin 
antagonist), baclofen (a GABAB agonist), aripiprazole (a dopamine partial 
agonist), rimonabant (a cannabinoid antagonist), and memantine (an NMDA 
antagonist). Nalmefene, a drug similar to naltrexone, is a non-selective opiate 
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antagonist, but has advantages over naltrexone such as a longer half-life and 
lower prevalence of side effects, particularly hepatotoxicity.28 Because of the 
different mechanisms of action for many of these agents, studies that combined 
some of these agents in order to improve therapeutic outcomes have also been 
initiated Considerable emphasis, however, appears to be on the evaluation of 
drugs that affect the dopaminergic, GABAergic and glutamatergic systems. 
18,26,27,29-33 
 
1.2 Cocaine Addiction 
1.2.1 Epidemiology 
The current percentage of cocaine users is not as high as users of other illicit 
drugs such as methamphetamine and marijuana, yet the considerable health and 
financial losses that result from cocaine addiction exceed other illicit drugs. The 
National Survey on Drug Use and Health (NSDUH) estimated that in 2007, there 
were 2.1 million current (past-month) cocaine users, of whom approximately 
610,000 were current crack users. Adults aged 18 to 25 years had a higher rate of 
current cocaine use than any other age group, with 1.7 percent of young adults 
reporting past month cocaine use. Repeated cocaine use can produce addiction 
and other adverse health consequences. In 2007, according to the NSDUH, nearly 
1.6 million Americans met the Diagnostic and Statistical Manual of Mental 
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Disorders, 4th Edition (DSM-IV) criteria for dependence on or abuse of cocaine 
(in any form) in the past 12 months. Since there is no accepted treatment for 
cocaine addiction, it has become even more important to develop possible 
pharmacological treatments.34-36 
 
1.2.2 Pharmacology 
There are basically two forms of cocaine: the hydrochloride salt and the 
“freebase.” The hydrochloride salt is the powdered form and is soluble in water. 
Freebase refers to the compound in a form that has not been protonated by an 
acid to make the hydrochloride salt. The principal routes of cocaine 
administration are oral, intranasal, and intravenous. Cocaine use ranges from 
occasional to compulsive use; there is no safe way to use it. Any route of 
administration can lead to absorption of toxic amounts of cocaine, leading to 
cardiovascular and cerebrovascular emergencies that result in death.37 The short 
term physiological effects of cocaine include constricted blood vessels, dilated 
pupils, increased temperature, increased heart rate, and increased blood pressure. 
Large amounts of cocaine intensify the feeling of euphoria, but may also lead to 
violent behavior and even death. Cocaine-related deaths often result from cardiac 
or respiratory arrest. The long-term use of cocaine leads to increased tolerance to 
the euphoric effects of the drug and paradoxically, increased sensitivity to the 
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drug’s anesthetic and convulsant effects. This may explain why some deaths 
occur among long-term users after relatively low doses of cocaine. The long term 
use of cocaine also leads to a state of increased irritability, restlessness and 
paranoia. This eventually leads to paranoid psychosis, in which the individual 
loses touch with reality and experiences hallucinations.37-39 As with alcohol, 
continued cocaine use results in development of tolerance. This means that higher 
doses and more frequent use of cocaine are required for the brain to register the 
same level of pleasure experienced by the initial use. Even after long periods of 
abstinence, the memory of euphoria associated with cocaine use or even cues 
associated with the drug, can trigger tremendous craving and relapse for the drug 
user. 37 
 
1.2.3 Neurochemistry 
1.2.3.1 Dopaminergic System 
The dopaminergic system in the brain plays an important role in the reward 
pathway in addiction.  Cocaine acts on the dopaminergic system by binding to the 
dopamine transporter and preventing dopamine reuptake at the pre-synaptic 
terminal, which subsequently leads to an increase in brain dopamine.7,40-42 This 
effect of cocaine is illustrated in figure 1.3. Thus cocaine acts like an indirect 
agonist on the dopamine receptor.  
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Figure 1.3 Effect of cocaine on dopamine neurotransmission. 
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There is considerable evidence that cocaine’s addictive ability is linked to 
reuptake blockade in CNS reward or reinforcement pathways, especially in the 
mesocorticolimbic system and particularly the nucleus accumbens.24  For 
instance, cocaine-induced increases in extracellular dopamine have been linked to 
its rewarding and craving effects in rodents.43 In humans, the pharmacokinetic 
binding profile of [11C]-cocaine indicated that the uptake of labeled cocaine was 
directly correlated with the self-reported ‘‘high.’’14,15  In light of the implication 
of dopamine in the mesolimbic and mesocortical systems in cocaine addiction, 
drugs that affect the dopaminergic pathway have been investigated for the 
treatment of cocaine abuse. While the dopamine hypothesis as it relates to cocaine 
addiction may explain some of the addicting processes, studies with drugs that 
affect the dopaminergic system have been inconsistent. For example, in positron 
emission tomography studies, methylphenidate, an inhibitor of dopamine 
reuptake, inhibited 50% of the dopamine transporter and enhanced extracellular 
dopamine.14 Yet in a 10-week study, methylphenidate was found to be ineffective 
in reducing cocaine use in patients.44 Bromocriptine is a D2 receptor agonist, and 
except for one positive outcome, other clinical studies did not support it as a 
useful agent for the treatment of cocaine abuse.45-47  
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1.2.3.2  GABAergic System 
The brain areas that contain dopaminergic neurons (nucleus accumbens) also 
contain GABAergic synapses.48 Several studies have shown that the GABAergic 
system can modulate dopamine levels in the nucleus accumbens. Vigabatrin, a 
drug that inhibits GABA-transaminase, blocked a cocaine-induced increase in 
extracellular dopamine in the nucleus accumbens.49,50 Another study showed that 
gamma-vinyl-GABA, which increases GABA levels in the brain, blocked 
cocaine-induced locomotor activity and dopamine release.51 Topiramate has been 
shown to potentiate GABAergic transmission. In a 14-week clinical study, 
topiramate decreased cocaine use compared with the control group.52 Tiagabine, a 
selective inhibitor of the GABA transporter, increases GABA in the synapse and 
in a study with opioid-dependent subjects, tiagabine blocked cocaine use 
compared with the control group.53 Gabapentin, a GABA analog, also reduced 
cocaine use in cocaine smokers.54 
 
1.2.3.3  Glutamatergic System 
The glutamatergic system has also received increased interest for its role in 
cocaine addiction. There is both anatomical and physiological evidence that 
glutamate neurotransmission modulates the function of the nucleus accumbens by 
interacting with dopamine. Glutamate releasing neurons originating in the 
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cerebral cortex, hippocampus, and amygdala projected onto neurons in the 
nucleus accumbens. Both non-competitive and competitive glutamate NMDA 
antagonists blocked cocaine-induced behavior.55,56 Considerable evidence exists 
that the antagonism of glutamate receptors affected cocaine self-administration.57 
Several studies have shown that the glutamatergic system can modulate the 
dopamine levels in the nucleus accumbens.58,59 The interactions between the 
glutamatergic and dopaminergic pathways are believed to play an important role 
in the relapse of cocaine seeking behavior and cocaine addiction.60,61 
 
1.2.4 Pharmacotherapeutics 
There are currently no approved treatments for cocaine addiction. Rather than 
develop new chemical entities for cocaine addiction, most of the treatment options 
have focused on CNS agents approved for other uses. Using this approach, several 
CNS drugs have been studied for the treatment of cocaine abuse. GABA agents 
(topiramate, tiagabine, baclofen and vigabatrin) and agonist replacement agents 
(modafinil, disulfiram and methylphenidate) appear to be the most effective in 
treatment of cocaine dependence. Aripiprazole, a partial dopaminergic agonist 
that may modulate the serotoniergic system, showed some efficacy against 
cocaine abuse. Preliminary results of human studies with anti-cocaine vaccines, 
N-acetyl cysteine and ondansetron are also promising. Vaccine pharmacotherapy 
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used anti-cocaine antibodies to sequester cocaine molecules in the peripheral 
circulation and prevented it from crossing the BBB. N-acetyl cysteine reduced 
cocaine-induced reinstatement of cocaine self-administration in rats. Ondansetron 
is a serotonin 5-HT3 receptor antagonist that increased dopamine activity in the 
nucleus accumbens of rats. These studies suggest that targets of interest in 
developing new treatments for cocaine dependence should include the 
dopaminergic, GABAergic and glutamatergic systems.28,31,40,62 
 
1.3 Disulfiram 
1.3.1 History of Disulfiram 
Disulfiram has been used as an alcohol deterrent since 1948, when it was first 
introduced by Hald and Jacobsen.63 Disulfiram is an inhibitor of mitochondrial 
low Km ALDH2, which catalyzes the oxidation of acetaldehyde to acetate. 
Ingestion of disulfiram followed by alcohol intake results in a build-up of 
acetaldehyde. This increase of acetaldehyde in the blood leads to the disulfiram-
alcohol reaction, which is characterized by nausea, vomiting, headache, 
hypotension, and tachycardia. The pharmacological basis of disulfiram is to use it 
to deter alcoholics from consuming alcohol rather than to produce this adverse 
reaction.64 
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1.3.2 Bioactivation of Disulfiram 
The pathways of disulfiram metabolism are shown in figure 1.4. Disulfiram is 
bioactivated through a series of intermediates, ultimately forming S- methyl N, N-
diethylthiocarbamate sulfoxide (DETC-MeSO), which has been proposed to be 
responsible for the ALDH2 inhibition.66-68 The metabolism of disulfiram is carried 
out by various cytochrome P450 enzymes in the liver. DETC-MeSO is a very 
reactive species and is oxidized to S- methyl N, N-diethylthiocarbamate sulfone 
(DETC-MeSO2), which carbamoylates glutathione to form carbamathione during 
phase II metabolism.69-73 
 
1.3.3 Clinical Trials with Disulfiram 
Acamprosate is a drug that is used in the treatment of alcoholism. Acamprosate is 
a structural analog of GABA and may have an effect on both GABAergic and 
NMDA receptors. These neurotransmitters act by sending inhibitory messages to 
the brain and acamprosate is thought to act by enhancing their inhibitory effects. 
Acamprosate is also thought to decrease the activity in excitatory glutamate 
receptors in the brain, which is believed to reduce the desire or craving to 
consume alcohol; hence its use in alcohol dependence.74 
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Figure 1.4 Bioactivation of disulfiram.65 
 
 
 
 
DDTC: diethyldithiocarbamate 
DDTC-Me: diethyldithiocarbamate methyl ester 
DETC-Me: S-methyl N ,N-diethylthiocarbamate 
DETC-MeSO: S- methyl N, N-diethylthiocarbamate sulfoxide 
DETC-MeSO2: S- methyl N, N-diethylthiocarbamate sulfone 
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In one placebo-controlled alcohol trial, acamprosate and disulfiram were 
prescribed to patients.75 The patients on the disulfiram-acamprosate combination 
had significantly more abstinent days than the patients that received acamprosate 
alone. In addition, there were no adverse interactions between acamprosate and 
disulfiram in 24 patients treated for 12 months. 
 
Another clinical trial in 2005 that investigated the effectiveness of acamprosate 
and disulfiram in alcohol treatment found disulfiram to be much more effective. 
Compared with acamprosate, disulfiram was associated with a significantly 
greater reduction in relapse and significantly more abstinent days.76 
 
Disulfiram has also been tested in clinical trials to determine its efficacy in 
cocaine treatment. Carroll et al. treated 121 outpatients for 12 weeks. The 32 
women and 89 men met the criteria for cocaine dependence as specified in the 
DSM-IV, and these volunteers reported abusing cocaine 13 days during the month 
and 2.5 days during the week before treatment on average. During the study, each 
patient received either 250 mg/day of disulfiram or a placebo. The trial showed 
that disulfiram helped cocaine addicts reduce abuse of the drug from 2.5 days a 
week to 0.5 days a week on average. The finding built on previous studies in 
which other investigators demonstrated disulfiram's promise in two subgroups of 
cocaine abusers—alcoholics and those with co-occurring opioid addiction. The 
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results suggested that disulfiram was effective in treating the general population 
of cocaine-addicted patients, including those that were not alcoholic. The 
medication's effectiveness in non-alcoholic patients provided evidence that 
disulfiram reduced cocaine abuse directly rather than by reducing the concurrent 
alcohol abuse.77 
 
1.4 Microdialysis 
1.4.1 Principles of Microdialysis 
Microdialysis is an in vivo sampling method by which chemical substances can be 
removed and introduced without removing or injecting fluids. The principle of 
microdialysis is based on the passive diffusion of a compound along its 
concentration gradient across a semi-permeable membrane (figure 1.5). 
Microdialysis involves the implantation of a microdialysis probe into a specific 
region of a tissue or fluid-filled space.  A variety of probe designs have been 
employed in the study of biological tissues including concentric, flexible, linear, 
and shunt or by-pass (figure 1.6). The semi-permeable membranes used to make 
microdialysis probes range from low- to high-molecular weight cutoffs.  
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Figure 1.5 Principle of microdialysis. 
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Figure 1.6 Commonly used probe designs78 
 
 
 
a. Rigid concentric probe typically used for brain microdialysis 
b. Flexible cannula probe typically used for implantation into a blood vessel 
c. Linear probe typically used to sample peripheral tissue such as skin or muscle 
d. Shunt or by-pass probe is usually used for sampling the bile duct 
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During microdialysis, a physiologically compatible perfusion fluid (perfusate 
such as Ringer’s solution) is pumped through the probe at a low and constant flow 
rate (typically 0.1-5.0 µL/min). Exchange of solutes occurs in both directions 
across the semi-permeable membrane of the probe, depending on the solute 
concentration gradients. Thus the probe can be used in delivery of compounds as 
well as in the sampling experiments.79,80 For a perfusate that lacks the compound 
of interest; the microdialysis sample concentration is usually a fraction of the 
extracellular unbound concentration of that compound in the tissue. This fraction 
is referred to as the extraction efficiency (EE). In investigations that examine 
changes in the levels of endogenous compounds from their baseline values, it may 
not be necessary to determine the EE, assuming the EE remains relatively 
constant throughout the experiment. However, in pharmacokinetic (PK) 
investigations without baseline values for exogenous substances, knowledge of 
the EE becomes crucial for the determination of true extracellular tissue 
concentrations.78,81-83 Many experimental conditions affect probe calibration, 
including perfusion rate, temperature, probe membrane composition, surface area, 
nature of the tissue, and properties of the analyte of interest. In general, higher 
perfusion flow rates lead to the lower EE whereas higher temperatures and greater 
probe membrane areas usually result in increased EE.83  
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Development and refinement of the microdialysis methodology over the past 20 
years has led to its increased acceptance in studies of drug distribution, 
metabolism, and pharmacodynamics (PD). However, one of the most important 
applications of microdialysis is in the measurement of compounds in the brain. 
These studies have examined not only neurotransmitters but also, in the past 
several years, the drug distribution to specific regions of the CNS. Microdialysis 
has permitted the investigation of the distribution kinetics and delivery of drugs to 
a wide variety of target tissues, allowing for the measurement of unbound, 
pharmacologically active drug levels over time in the relevant species and 
tissue.84,85 
 
1.4.2 Microdialysis Calibration Methods 
Calibration methods are important in microdialysis experiments when quantitative 
information on extracellular fluid concentrations is desired.  Although EE may 
approach 100% for long probes and slow flow rates, the commonly used perfusate 
flow rate (1-2 µL/min) and membrane length (2-10 mm) usually result in EE that 
are much less than 100% in animal experiments. In addition, microdialysis 
sampling is usually carried out under non-equilibrium conditions since the 
perfusate is continuously pumped through the probe. The general equation to 
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determine microdialysis probe EE by the ratio of concentration (C) of analyte in 
the dialysate and the sample is as follows86-88: 
 
ܧܧ = ஼೛೐ೝ೑ೠೞೌ೟೐ି஼೏೔ೌ೗೤ೞೌ೟೐
஼೛೐ೝ೑ೠೞೌ೟೐ି஼೟೔ೞೞೠ೐
                                        (1) 
 
In vivo the Ctissue cannot be determined directly, so the use of microdialysis 
sampling as a quantitative tool relies on the determination of the EE. A number of 
methods have been used to calculate the EE of microdialysis probes. The most 
frequently used calibration methods are the low-flow-rate method, the no-net-flux 
(or zero-net-flux) method, the dynamic (or extended) no-net-flux method, 
retrodialysis and calibration by delivery of analyte.86-90 The general requirement 
of these methods is that the extraction fraction is the same whether the solute 
exchange across the membrane occurs by either loss or gain as predicted by the 
linear models. The low-flow-rate method is based on the assumption that EE is 
close to 100% and is generally applied in clinical microdialysis with longer 
probes and low flow rates (≤0.3 µL/min). The no-net-flux method requires steady-
state concentration in the tissue, whereas perfusate concentrations are changed in 
several discrete steps within one experiment. The dynamic no-net-flux method 
allows for time-varying in vivo concentrations, but this approach requires that 
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probes be perfused with a different constant concentration in at least three 
different groups.83,86,88,90  
 
The most common calibration method is retrodialysis by marker compound, 
which is performed before or after analyte administration without the analyte 
being present in the tissue. The advantage is that the solute of interest is 
measured; however, a drawback is that possible changes in EE over time are not 
measured. This method is not applicable to endogenous compounds because the 
requirement of no concentration in the tissue during the calibration interval cannot 
be met. Changes in EE during the experiment can be partially taken into account 
via retrodialysis by a marker compound. A good marker should have similar 
diffusion, transport, and if necessary similar metabolism properties as the analyte 
of interest.  The ideal standard is thus a deuterated or radioactive form of the 
analyte; however, labeling an analyte can be expensive. In addition, the marker 
must be analytically distinguishable from the analyte in order to monitor both 
compounds. Finding a compound with analogous properties of transport through 
the probe makes retrodialysis a difficult method for probe calibration.80,82,91 
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An alternate calibration method to retrodialysis is to determine the EE of the 
microdialysis probe by delivery of analyte of interest through the probe. A low 
concentration of the analyte is perfused through the probe and microdialysis 
samples are analyzed once a steady state of delivery is achieved.83 The extraction 
efficiency by delivery (EEd) is derived from equation 1. For delivery studies, there 
is no initial concentration of analyte in the tissue so the equation becomes: 
 
ܧܧௗ = ஼೛೐ೝ೑ೠೞೌ೟೐ି஼೏೔ೌ೗೤ೞೌ೟೐஼೏೔ೌ೗೤ೞೌ೟೐                                            (2) 
 
For recovery studies, there is no analyte in the perfusate so the EE, derived from 
equation 1 becomes: 
ܧܧ௥ = ஼೏೔ೌ೗೤ೞೌ೟೐஼೟೔ೞೞೠ೐                                                    (3)                                    
 
Transport across the probe should be independent of direction, therefore, equal for 
both the delivery and recovery. By this assumption, the EEd value equals the EEr. 
Therefore, the analyte concentration in the tissue of interest (Ctissue), can be 
calculated by determining the concentration in the dialysate (Cdialysate) and 
substituting the EEd for the extraction efficiency by recovery (EEr) in equation 
3.83,89 
 
 31 
1.4.3 Tissue Response to Probe Implantation 
Microdialysis probe implantation in tissues inevitably leads to immune reactions, 
particularly when the probe is implanted for extended periods. These reactions 
have been well-characterized in the literature and tend to be consistent. After 
implantation, a small amount of hemorrhaging occurs around the implantation sit, 
but contact between the tissue and membrane is still maintained. Inflammation is 
the initial acute immune response of the tissue and it lasts 3 to 4 hours after 
implantation. Blood flow increases to the implantation site and neutrophils begin 
to infiltrate, surrounding the probe. Eight hours after implantation, neutrophil 
infiltration continues to increase and some necrosis is evident. 1-3 days after 
probe implantations, macrophages infiltrate and begin to remove the necrotic 
tissue and any bacteria present. For extended implants (1 week or more), the 
tissue eventually begins to generate a capsule of connective tissue around the 
probe to isolate it from the rest of the tissue. Angiogenesis also occurs with the 
fibrous capsule.92,93 
 
To allow “tissue equilibration” (i.e., to provide time for the initial trauma to 
subside), probe perfusion for more than half an hour has shown to be sufficient 
before starting probe calibration, although longer recovery times (12-24 hours) 
may be required. This is based on the finding that several markers of tissue 
trauma (e.g., thromboxane B2, adenosine triphosphate, adenosine, K+, glucose, 
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lactate, lactate/pyruvate ratio) are elevated after probe insertion and reach baseline 
or become undetectable within this time range.94,95 
 
 One of the controversial questions addressed in CNS microdialysis research is the 
integrity of the BBB after probe implantation. It was shown that the BBB 
maintained its chemical selectivity with respect to mannitol and tritiated water.96 
Additional studies indicate a functional BBB in terms of passive and active 
transport mechanisms when optimal surgical and experimental conditions are 
employed in implanting microdialysis probes into the brain.96,97 
 
1.4.4 Pharmacokinetic and Pharmacodynamic Studies with Microdialysis 
In order to measure the relationship between drug concentrations in the blood 
(PK) and drug response (PD) it is essential to measure the drug in the tissue that 
represents the specific site of action. Microdialysis allows the sampling of the 
extracellular fluid of tissue and thus generates more relevant data than serum or 
plasma concentrations alone. For drugs that affect the CNS, a complex 
relationship exists between the dose and the response. Factors such disease 
condition, age, and weight all affect the response to a drug. Microdialysis can be 
particularly useful in these kinds of mechanism-based PK and PD studies of 
drugs.  Several key mechanisms govern the dose-response relationship of drugs, 
 33 
including plasma PK, BBB transport, tissue distribution, pathological conditions 
and drug-target interaction. Microdialysis is well suited to determine passive and 
active membrane transport mechanisms, such as those of the BBB. Intercellular 
chemical communication in the brain occurs via the extracellular fluid and an 
added advantage of microdialysis is that extracellular biomarkers of drug response 
and disease progression can be sought and monitored.81,91,98-100 
 
1.5 Analytical Methods for Neurotransmitters in Microdialysis Samples 
In neurochemistry, the in vivo monitoring of the extracellular concentrations of 
neurotransmitters plays a key role in the understanding of the molecular, 
electrophysiological, or behavioral events. Microdialysis is a frequently used 
technique to continuously sample the extracellular space of discrete brain regions. 
The microdialysis technique is a suitable method for this purpose in comparison 
to biosensors, which can detect only one neurotransmitter at a time.101,102 
Moreover, microdialysis is an ideal tool for the study of in vivo extracellular 
neurotransmitter levels in relationship to pharmacotherapeutic agents.  Other 
sampling methods such as the push-pull technique and homogenization cause 
more tissue damage than microdialysis. In addition, tissue homogenization 
destroys neurotransmitter compartmentalization since it cannot be used to 
differentiate between released or free neurotransmitters and intercellular stores.  
 34 
The microdialysis technique requires a small-diameter (<300 µm) dialysis tube to 
be stereotaxically implanted in a defined brain area. The neurotransmitters in the 
collected microdialysis samples can be identified and measured either online or 
after storage. As a sampling tool, microdialysis can be coupled to a variety of 
analytical techniques allowing virtually any neurotransmitter or drug to be 
measured with high selectivity and sensitivity. In many cases, multiple analytes 
can be detected in one sample, which facilitates studies of neurotransmitter 
interactions. Because samples can be collected over time, microdialysis can be 
used to obtain both basal concentrations and dynamic information on brain 
chemistry. 103,104 
 
Analysis of microdialysis samples from the brain has conventionally used 
classical high-performance liquid chromatography (HPLC) with electrochemical 
or fluorometric detection, and also enzymatic or radioenzymatic methods.102,105-108 
However, these analytical techniques exhibit poor concentration sensitivity and 
require large volume samples to determine neurotransmitter contents, leading to 
lengthy sampling times (15–30 min), although this requirement has been reduced 
by the breakthrough of microbore HPLC.78,105,109,110 The temporal resolution is 
even worse when samples have to be split for the simultaneous determination of 
different classes of neurotransmitters. As a consequence, most of the previous 
microdialysis experiments were severely limited by the temporal resolution of 
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microdialysis (10–30 min) compared with rapid changes occurring in the 
extracellular concentrations of neurotransmitters. 
 
In contrast, microdialysis coupled to capillary electrophoresis (CE), a more recent 
technique, can allow the monitoring of rapid changes in the extracellular 
concentration of neurotransmitters. CE is able to analyze nanoliter volume 
samples with low limits of detection and appears to be suitable for microdialysis 
at high sampling rates. Recent studies show significant progress in high temporal 
resolution monitoring of neurotransmitters with sampling times of 10-30 s being 
utilized.111-114 
 
For the last few years, CE mainly coupled to laser-induced fluorescence (LIF) 
detection has been explored as an alternative to conventional analytical techniques 
for the determination of various compounds in biological fluids.115-117 In brain 
microdialysis samples, excitatory amino acids (i.e. glutamate and aspartate) and 
GABA were often analyzed, and to a lesser extent catecholamines, dopamine, and 
noradrenaline.112,115,118-120 Since none of these compounds have native 
fluorescence, a number of reagents have been utilized in derivatization reaction to 
employ LIF detection. Some of these reagents include o-phthalaldehyde (325 nm), 
naphthalene-2, 3-dicarboxaldehyde (442 nm), fluorescein isothiocyante (488 nm), 
and imidazole naphthalene-2, 3-dicarboxaldehyde (488 nm).  
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Micellar electrokinetic chromatography (MEKC), a modification of CE, has been 
used recently in combination with LIF for the simultaneous detection of several 
amino acid neurotransmitters and catecholamines.119,121,122 MEKC is performed 
by adding an ionic micelle such as sodium dodecylsulfate (SDS) to the running 
solution of CE without modifying the instrument. The separation principle of 
MEKC is based on the differential migration of the ionic micelles and the bulk 
running buffer under electrophoresis conditions and on the interaction between 
the analyte and the micelle. Hence MEKC's separation principle is similar to that 
of chromatography. MEKC is a useful technique particularly for the separation of 
small molecules, both neutral and charged, and yields high-efficiency separation 
in a short time with minimum amounts of sample and reagents.  
 
SDS is the most commonly used surfactant in MEKC applications. The anionic 
character of the sulfate groups of SDS cause the surfactant and micelles to have 
electrophoretic mobility that is counter to the direction of the strong 
electroosmotic flow. As a result, the surfactant monomers and micelles migrate 
quite slowly, although their net movement is still towards the cathode. During a 
MEKC separation, analytes distribute themselves between the hydrophobic 
interior of the micelle and hydrophilic buffer solution as shown in figure 1.7. 
MEKC allows the efficient separation of biogenic amines and amino acids in 
biological samples. The MEKC-LIF methods that have been used recently 
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displayed good specificity, sensitivity, reliability, and efficiency of separation and 
detection for a large number of neurotransmitters. 
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Figure 1.7 Principle of micellar electrokinetic chromatography.123 
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2 IN VIVO MICRODIALYSIS AND CE-LIF FOR MONITORING 
GABA, GLUTAMATE, AND CARBAMATHIONE 
2.1 Introduction 
The first step in determining the pharmacokinetics (PK) and pharmacodynamics 
(PD) of carbamathione is the development of a method to separate and detect 
carbamathione and the relevant neurotransmitters simultaneously in a 
microdialysis samples. The development of this method would allow the 
monitoring of carbamathione-induced changes in the neurotransmitters. The 
following chapter describes a capillary electrophoresis in conjunction with laser-
induced fluorescence (CE-LIF) method that was developed to achieve this goal. 
 
2.1.1 Effect of Carbamathione on GABA and Glutamate 
There has been renewed interest in disulfiram due to recent clinical trials. 
Disulfiram was effective in reducing cocaine and alcohol consumption and was 
reported to reduce craving. Disulfiram is a pro-drug that requires bioactivation to 
S- methyl N, N-diethylthiocarbamate sulfoxide (DETC-MeSO) for the inhibition 
of aldehyde dehydrogenase (ALDH2).1-3 Another disulfiram metabolite, 
carbamathione is formed after DETC-MeSO and was found in the brain after 
administration of both disulfiram and DETC-MeSO.4,5 Carbamathione has no 
effect on liver ALDH2 when administered to rodents, but studies show 
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carbamathione is a partial non-competitive inhibitor of the N-methyl-D-aspartic 
acid (NMDA) glutamate receptor.4,6 Evidence in the literature suggests that the 
glutamatergic and GABAergic systems may play a role in ethanol addiction.7-11 In 
light of carbamathione’s effect on the NMDA receptors, it was important to study 
the effect of carbamathione administration on brain glutamate (Glu) and gamma-
amino butyric acid (GABA) levels as a step towards providing an explanation for 
disulfiram’s efficacy in clinical trials. 
 
2.1.2 CE-LIF for Neurotransmitters in Biological Samples 
CE allows the monitoring of rapid changes in brain neurotransmitters with very 
small volume requirements. CE-LIF has recently been used to determine various 
compounds in biological samples.12-14 In the brain microdialysis samples, 
excitatory amino acids such as Glu and GABA have been analyzed.15,16 Since 
neurotransmitters are not natively fluorescent, derivatization prior to separation is 
required.17-19 For this study, napthalene-2,3-dicarboxyaldehyde  (NDA) was 
chosen since it is not fluorescent itself and it reacts rapidly to give stable 
fluorescent cyanobenzo[f]isoindol (CBI) derivatives. The derivatization of the 
primary amine provided the added advantage of including carbamathione in the 
analysis of a sample since it is also a primary amine. The derivatization scheme of 
NDA is shown if figure 2.1. 
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Figure 2.1 NDA derivatization scheme. 
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2.1.3 Specific Aims of Research 
The goal of this research was to apply CE separation methods to determine the 
changes (if any) in the amino acid neurotransmitters from the nucleus accumbens 
of a rat brain as related to the administration of carbamathione. Existing CE 
separation methods were modified and optimized in order to include 
carbamathione in the analysis of GABA and Glu. Since carbamathione has a 
primary amine functional group (figure 2.2), it can be derivatized along with 
GABA and Glu using the NDA derivatization scheme. The derivatives were 
detected using LIF detection. The required limits of detection and quantification 
for the analytical method were based on the known concentrations of GABA, Glu 
and carbamathione in the nucleus accumbens. The expected concentration range 
for GABA and Glu in microdialysis samples from rat brain nucleus accumbens 
are 40-100 nmol/L and 0.7-2.5 µmol/L, respectively.12,20-22 Previous studies with 
carbamathione have demonstrated that micromolar concentrations of 
carbamathione were detected in rat brain dialysate after a 200 mg/kg dose of 
carbamathione.23 The temporal resolution achieved for this method was 5 min. 
The neurotransmitter and carbamathione data were used to establish PK and PD 
relationships between the administration of the drug and changes in the 
neurotransmitter systems.  
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Figure 2.2 Structure of carbamathione. 
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2.2 Experimental 
2.2.1 Chemicals and Reagents 
Napthalene-2, 3-dicarboxyaldehyde (NDA) was purchased from Invitrogen 
(Molecular Probes, Eugene, OR, USA). Sodium cyanide (NaCN) was purchased 
from Fluka (Buchs, Switzerland). Glutamate (Glu), gamma-amino butyric acid 
(GABA), 2-aminoadipic acid (AAP), sodium tetraborate, boric acid, and 
perchloric acid were purchased from Sigma (St. Louis, MO, USA).  Sodium 
bicarbonate (NaHCO3), sodium chloride (NaCl), potassium chloride (KCl), 
magnesium chloride (MgCl2), calcium chloride (CaCl2), monosodium phosphate 
(NaH2PO4), disodium hydrogen phosphate (Na2HPO4), sodium hydroxide 
(NaOH), hydrochloric acid (HCl), ethanol, methanol (MeOH), and acetonitrile 
(ACN) were purchased from Fisher Scientific (Pittsburgh, PA, USA). Isoflurane 
and ketamine were purchased from Fort Dodge Animal Health (Fort Dodge, IA, 
USA). Xylazine was purchased from Lloyd Laboratories (Shenandoah, IA, USA). 
Acepromazine was purchased from Boehringer Ingelheim Vetmedica, Inc. (St. 
Joseph, MO, USA). VetBond tissue glue was purchased from 3M (St. Paul, MN, 
USA). Lactated Ringer’s was purchased from B Braun Medical Inc. (Irvine, CA, 
USA). Ultrapure water was obtained with a Milli-Q system (Millipore, Bedford, 
MA, USA).  
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Carbamathione was synthesized using methods previously developed.6,24 The 
structure of carbamathione was confirmed by mass spectrometry and nuclear 
magnetic resonance (NMR 1H, D2O).5 Exact mass determination of [M + H]+ 
C15H27N4O7S was 407.1594 ± 0.0014 (n = 4) which was 2.3 ppm from the 
expected mass. The NMR chemical shifts were δ 1.14 m 6H ((CH3CH2)2N-), δ 
2.11 m 2H (Glu- β,β’), δ 2.45 m 2H (Glu-γ,γ’), δ 3.15 m 1H (Cys- β), δ 3.37 m, 
5H (CH3CH2)2N-, Cys- β), δ 3.81 t 1H (Glu-α), δ 3.85 s 2H (Gly-α,α’), δ 4.55 t, 
1H (Cys- α). The purity of the carbamathione synthesized was determined by 
HPLC with UV detection at 215 nm. A sample of 1000 nmol/L concentration 
gave a chromatogram with signal-to-noise ratio (S/N) > 100 and there was no 
other detectable peak. Liquid chromatography coupled with mass spectrometry 
(LC/MS) injections of the standard revealed no other MS detectable peaks during 
the LC gradient. LC-MS/MS was also used to evaluate the stability of the 
synthesized carbamathione under different temperature and storage conditions. 
Samples of carbamathione were subjected to room temperature (25° C), -20° C, 
and three freeze-thaw cycles.  Stability data are shown in table 2.3. 
Carbamathione was determined to be stable under different temperature and 
storage conditions. All the samples evaluated displayed variability of less that 
10% relative standard deviation (R.S.D.).  
 
 
 66 
Table 2.3 Stability of carbamathione under various conditions using LC-MS/MS. 
All stability studies were conducted at three concentrations of carbamathione (5.0 x 10-9, 1.0 x   
10-7, 5.0 x 10-6 mol/L) with three determinations each.  
 
Storage Conditions Concentration (mol/L) RSD (%) 
  Nominal Mean Measured   
Freeze-thaw stability 5.0 x 10-9 5.520 8.0% 
  1.0 x 10-7 101.3 3.4% 
  5.0 x 10-6 5167 5.5% 
Stability at room temperature (2h) 5.0 x 10-9 4.979 7.0% 
  1.0 x 10-7 102.5 5.1% 
  5.0 x 10-6 5041 2.7% 
Stability at room temperature (4h) 5.0 x 10-9 4.779 9.0% 
  1.0 x 10-7 95.55 6.9% 
  5.0 x 10-6 5111 6.3% 
Stability at -20° C (10 days) 5.0 x 10-9 4.583 7.4% 
  1.0 x 10-7 103.4 2.8% 
  5.0 x 10-6 5016 6.6% 
Stability at -20° C (20 days) 5.0 x 10-9 5.060 8.2% 
  1.0 x 10-7 105.8 3.9% 
  5.0 x 10-6 5088 8.7% 
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Artificial cerebrospinal fluid (aCSF) contained 145 mmol/L NaCl, 2.7 mmol/L 
KCl, 1.0 mmol/L MgCl2, 1.2 mmol/L CaCl2, 0.45 mmol/L NaH2PO4, and 2.33 
mmol/L Na2HPO (pH 7.4). The aCSF was filtered through a 0.2-µm pore size 
cellulose acetate membrane filter and stored at room temperature (25° C). 
Standard solutions of amino acids (1 mmol/L each) were dissolved in 0.1 mol/L 
perchloric acid and stored at 4° C. Borate buffer for derivatization was obtained 
by dissolving 7.73 g of boric acid and 11.92 g of sodium tetraborate, respectively 
in 250 mL of ultrapure water each. The pH of the sodium tetraborate solution was 
measured with a pH-meter and adjusted until 8.7 with the boric acid solution. A 3 
mmol/L NDA solution was prepared in ACN-water (50:50, v/v) weekly and 
stored at 4° C. An 87 mmol/L NaCN solution was prepared in ultrapure water and 
stored at 4° C. The background electrolyte (BGE) consisted of 50 mmol/L boric 
acid. The pH of the solution was adjusted to 9.6 with a 1 mol/L NaOH solution. 
 
2.2.2 Derivatization 
A borate-NaCN solution (100:20, v/v) was prepared by adding 20 µL of 87 
mmol/L NaCN to 100 µL of the derivatization borate buffer. On the day of 
analysis, 5 µL of dialysate sample and 5 µL of standards were derivatized at room 
temperature (25° C) by adding 1 µL of internal standard (10 µmol/L AAP), 1 µL 
of the borate-NaCN solution and 1 µL of 3 mmol/L NDA solution. 
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2.2.3 CE-LIF Instrumentation 
The electrophoretic system consisted of an automatic P/ACE MDQ system 
(Beckman-Coulter, Fullerton, CA, USA) equipped with an external LIF detector 
(ZETALIF, Picometrics, Toulouse, France). The excitation was performed by a 
helium-cadmium laser (Omnichrome, Chino, CA, USA) at a wavelength of 442 
nm. A 50 µm id fused-silica capillary (Polymicro Technology, Phoenix, AZ, 
USA) was used (75 cm total length, 60 cm effective), with a separation voltage of 
27.5 kV for 12 min. Each day, before the analyses were performed, the capillary 
was sequentially flushed at 20 psi with MeOH for 5 min, ultrapure water for 2 
min, 1 mol/L HCl for 5 min, ultrapure water for 2 min, 1 mol/L NaOH for 10 min, 
ultrapure water for 2 min and finally with the BGE for 5 min. Between analyses, 
the capillary was flushed at 20 psi with 1 mol/L NaOH for 3 min, with ultrapure 
water for 0.5 min and then with the BGE for 1.5 min. All the solutions injected 
onto the capillary were sterilized using a disposable 0.22 m polyethersulfone 
(PES) membrane syringe filter (Millipore, Co. Cork, Ireland). Samples were 
introduced by hydrodynamic injections for 5 s at 0.5 psi. Electropherograms were 
acquired on Beckman 32 Karat software.  
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2.2.4 Method Development 
Experiments to optimize the separation buffer were carried out using standards of 
GABA, Glu, and carbamathione prepared in aCSF and rat brain microdialysis 
samples. The separation of GABA, Glu, carbamathione and the internal standard 
(IS) was studied by varying the concentration and pH of the boric acid solution. 
Increasing the concentration of boric acid (figure 2.4) and increasing the pH 
(figure 2.5) both resulted in increased resolution and migration times. However, 
when 75 mmol/L boric acid or a buffer at pH 10 was used, the currents generated 
at higher separation voltages (> 22.5 kV) resulted in joule heating. When 25 
mmol/L boric acid or a pH 9.2 buffer was used, poor peak shapes were observed 
with a marked increase in the peak widths of GABA and carbamathione (see 
figures 2.3 and 2.4). The run buffer ultimately chosen for the separation was 50 
mmol/L boric acid at pH 9.6 because it represented a good compromise between 
run time and peak resolution. In addition, the currents produced with this buffer 
did not result in joule heating when voltages up to 30 kV were applied. The 
resolution data with this buffer indicated good separation between standards (R > 
1.5) for all pairs tested.  
 
Peak identification in microdialysis samples were carried out by comparing 
migration times with those present in standards (figure 2.6). 
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Figure 2.4 Effect of varying the concentration of BGE on separation. 
Effect of increasing boric acid concentration on separation of NDA-derivatized GABA (1), 
carbamathione (2), IS (3), and Glu (4). IS was AAP. Electropherograms were obtained using 
varying concentrations of boric acid buffer (pH 9.6) under a 27.5 kV voltage. NDA-derivatized 
compounds were detected using LIF detection (ex. 442 nm).  
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Figure 2.5 Effect of varying pH of BGE on separation. 
Effect of pH acid concentration on separation of NDA-derivatized GABA (1), carbamathione (2), 
IS (3), and Glu (4). IS was AAP. Electropherograms were obtained using 50 mmol/L boric acid 
buffer at varying pH levels under 27.5 kV voltage. NDA-derivatized compounds were detected 
using LIF detection (ex. 442 nm).  
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Figure 2.6 Typical CE-LIF electropherograms. 
Electropherograms of standard solution (A) containing GABA (1), carbamathione (2), and Glu (4) 
compared to dialysate obtained from rat brain (B).  IS (3) was AAP. Electropherograms were 
obtained using 50 mmol/L boric acid buffer (pH 9.6) under a 27.5 kV voltage. NDA-derivatized 
compounds were detected using LIF detection (ex. 442 nm).  
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In addition, the observed height of the peaks of interest increased when 
exogenous Glu and GABA were added to the microdialysis samples. No 
additional peaks appeared when Glu and GABA were added. Background peaks 
associated with NDA derivatization did not interfere with any of the analytes of 
interest.  
 
A 5 s sample hydrodynamic injection at 0.5 psi was chosen because it was a good 
compromise between separation and sensitivity. It was observed that if time of 
injection was increased, the width of the peaks increased and analytes were less 
separated. Voltages between 20-30 kV were tested and the best separation was 
obtained at 27.5 kV.  
 
In summary, separations were carried out using 50 mmol/L boric acid buffer at 
pH 9.6 and a running voltage of 27.5 kV in 75 x 50 µm id fused-silica capillary 
(60 cm effective). Separations were performed at room temperature (25° C). 
Figure 2.6 shows a typical electropherogram of derivatized microdialysis sample 
from the rat brain nucleus accumbens spiked with IS.  
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2.2.5 Method Validation Experiments 
Calibration standards for method validation contained GABA prepared in a 
concentration range of 10-9- 10-6 mol/L, Glu in a concentration range of 10-9- 10-6 
mol/L and carbamathione prepared in a range of 10-8- 10-5 mol/L. Calibration 
plots were plotted as the ratio of the area of compound of interest to area of the 
internal standard versus concentration (number of concentrations of each analyte, 
n = 7). The limits of detection and quantification were calculated as the analyte 
concentration that resulted in peaks with signal-to-noise ratio (S/N) of 3 and 10, 
respectively. Intra-day and inter-day reproducibility were determined using 
standards of Glu, GABA, and carbamathione prepared in aCSF and microdialysis 
samples. The accuracy of the method was calculated from the analysis of 
standards in aCSF, microdialysis samples and microdialysis samples spiked with 
known concentrations of standards (in triplicate). 
 
2.2.6 Microdialysis 
2.2.6.1 Brain Probes 
Microdialysis samples were obtained from the brain utilizing microdialysis probes 
with 2 mm membranes purchased from CMA Microdialysis (North Chelmsford, 
MA, USA). The relative recovery of carbamathione through the microdialysis 
probes were estimated by delivery experiments.25 Delivery experiments were 
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carried out by perfusing 1 µmol/L carbamathione through the microdialysis 
probes in vivo at 1 µL/min, and determining the percentage that diffused through 
the membrane. 
 
2.2.6.2 Animals and Surgery 
All experiments were carried out in accordance with Institutional Animal Care 
and Use Committee (IACUC) animal protocols. Male Sprague Dawley rats 
weighing 300-400 g were used for all experiments. The rats were housed in 
temperature controlled rooms with access to food and water ad libitum prior to 
surgery. The rats were initially anesthetized by isofluorane inhalation followed by 
an subcutaneous (s.c.) injection of a ketamine (67.5 mg/kg), xylazine (3.4 mg/kg) 
and acepromazine (0.67 mg/kg) mixture. Booster doses of ketamine (1:4 dilution 
with Ringer’s solution) were administered by intramuscular (i.m.) injections in the 
anesthetized experiments. Incision sites were prepared by shaving away as much 
hair as possible. For awake animal experiments, sterile surgeries were conducted. 
The microdialysis probes and surgical instruments were sterilized by ethylene 
oxide. The incision sites were prepared by shaving and washing with alternating 
scrubs of Prodine (Phoenix Pharmaceutical, Inc., St. Joseph, MO, USA) and with 
a 70% (v:v) solution of aqueous ethanol. The rat’s body temperature was 
maintained during the surgical procedure by placing the animal on microwaveable 
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heating pads. After the surgical procedures, the rats were administered 0.5 to 3 
mL/kg of saline s.c. to prevent dehydration. 
 
The femoral vein of the rat was cannulated for intravenous (i.v.) dosing. A small 
midline skin incision was made on the inside of the leg and the femoral blood 
vessels were located.  The large blue vein was cleared from fine connective tissue 
by blunt dissection and cotton swab.  The femoral vein was externalized by 
placing a spatula under it perpendicular to the axis of the vein.  A 1 cm section of 
femoral vein was temporarily ligated with silk ligatures.  Using a pair of fine 
spring scissors a nick was made between ligatures and a PE-10 cannula was 
inserted into the femoral vein to the vena cava lumen.  The femoral vein was 
ligated on either side of the cut.  The femoral cannula was then filled with saline 
solution and stoppered until dosing. The brain probe was implanted as previously 
described.5 Briefly, the rat was placed in a stereotaxic apparatus to implant the 
brain probe. The coordinates of the insertion site, the nucleus accumbens shell, 
relative to the bregma line were +2.2 mm anterior, +1.5 mm lateral and −6.5 mm 
ventral, according to the rat stereotaxic atlas.26 A guide cannula was lowered into 
the nucleus accumbens using a micromanipulator and fixed in place using skull 
screws and dental cement. The guide cannula was later replaced with the brain 
probe. For the awake animal experiments, the femoral cannula was externalized 
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through a sterile incision in the neck. All incisions were closed with stitches or 
surgical staples. 
 
2.2.6.3 Microdialysis Sample Collection 
Microdialysis samples were collected using a CMA 100 microinfusion pump and 
a HoneyComb fraction collector (Bioanalytical Systems Inc., West Lafayette, IN, 
USA). Connection of the microinjection pump and the fraction collector to the 
microdialysis probes was accomplished with tubing connectors (Bioanalytical 
Systems Inc., West Lafayette, IN, USA). After implantation, the brain probes 
were perfused with aCSF at 1 µL/min. For the awake animal experiments, the rats 
were placed in a rat turn equipped with a swivel arm (Bioanalytical Systems Inc., 
West Lafayette, IN, USA) as shown in figure 2.7. The dead volume between the 
dialysis site and the fraction collector was also determined in order to accurately 
monitor the neurochemical changes. The delay due to the dead volume was 
estimated to be 685 s and upon the administration of carbamathione, microdialysis 
samples were collected after this period of time.  
 
2.2.6.4 In Vivo Experiments 
The collection of 5 min samples was initiated after a 3 h waiting period for 
anesthetized experiments and a 24 h waiting period for awake experiments.  
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Figure 2.7 Swivel-based awake animal system 
 
 
 
www.microdialysis.se 
 
 
 
 
 
 
 
 
 
 79 
For dosing purposes, the carbamathione dose (200 mg/kg) was prepared by 
adding a few drops of 1 mol/L NaHCO3 solution and bringing the volume up to 1 
mL with saline solution. After the i.v. administration of carbamathione through 
the femoral cannula, microdialysis samples were collected for 3 h. At the end of 
the experiments, the rats were sacrificed by placement in an isofluorane chamber 
for approximately 30 min. Rat brains were harvested in order to perform a 
histological confirmation of brain probe position.  
 
2.3 Results and Discussion 
2.3.1 Method Validation Results 
Validation was carried out in accordance with instructions for good laboratory 
practice.27,28 Validation parameters were determined for GABA, Glu, and 
carbamathione in standards as well as brain microdialysis samples. The final 
results are shown in table 2.8. The regression coefficient of the calibration 
obtained with standard solutions and microdialysis samples showed good linearity 
and led to the routine use of only three points of the calibration curve. Limits of 
detection and quantification were lower than concentrations measured in 
microdialysis samples from the nucleus accumbens.  
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Table 2.8 Quantitative parameters for the analysis GABA, Glu, and carbamathione 
in aCSF and microdialysis samples. 
 
 aCSF GABA Glu Carbamathione 
Calibration range (mol/L) 10-9-10-6 10-9-10-6 10-8-10-5 
Regression coefficient of calibration (r²) 0.9969 0.9981 0.9990 
Intra-assay repeatability (%RSD)a 9.7 8.4 7.5 
Intra-day repeatability (%RSD)a 6.2 3.9 4.8 
Inter-day repeatability (%RSD)b 8.0 3.1 5.3 
Accuracy (%)c 2.2-1.1 1.5-0.9 4.1-1.5 
Limits of detection (mol/L) 1.0 x 10-8 6.0 x 10-9 1.5 x 10-8 
Limits of quantification (mol/L) 5.0 x 10-8 3.0 x 10-8 6.0 x 10-8 
 Microdialysis Samples GABA Glu Carbamathione 
Calibration range (mol/L)d 10-9-10-6 10-9-10-6 10-8-10-5 
Regression coefficient of calibration (r²) 0.9950 0.9978 0.9970 
Intra-assay repeatability (%RSD)a 11.5 9.4 8.8 
Intra-day repeatability (%RSD)a 7.5 6.7 6.1 
Accuracy (%)c,d 7.6-3.6 2.8-1.1 3.0-1.9 
 
a. Ten replicates 
b. Ten days, three replicates each 
c. Three replicates, tested concentrations of 10-7- 5 x 10-7 mol/L for GABA, Glu and 
carbamathione 
d. Spiked microdialysis samples (the added volume represents 10% of the microdialysis 
sample volume) 
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2.3.2 Microdialysis Probe Calibration 
The characteristics of the implanted microdialysis probes were evaluated at the 
end of each experiment. Based on the delivery experiments, the in vivo extraction 
efficiency by delivery (EEd) (mean ± standard error of mean [SEM], n = 3) for 
carbamathione was determined to be 10.8 ± 1.5% for the brain probes. The 
concentrations of carbamathione determined in the microdialysis samples were 
corrected for the EEd of the probe used. The in vitro extraction efficiency by 
recovery (EEr) (mean ± SEM, n = 3) for GABA and Glu was estimated to be 9.5 ± 
0.8% and 12.9 ± 1.1% respectively.  The concentrations of GABA and Glu were 
expressed as percent (mean ± SEM) of baseline concentrations in order to monitor 
changes from basal levels upon administration of carbamathione.  
 
2.3.3 Histological Confirmation of Brain Probe Position 
Microdialysis probe locations were examined histologically after completion of 
the experiments. After the rats were euthanized by isofluorane inhalation, the 
brains were removed and fixed in buffered formalin (10%). The tissues from the 
nucleus accumbens were embedded in paraffin wax and stained with 
hematoxylin-eosin. Only probes with at least 85% of the active dialysis membrane 
in the nucleus accumbens were included in the study. The representative location 
of microdialysis probe in the nucleus accumbens shell is shown in figure 2.9. 
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Figure 2.9 Representative location of microdialysis probe in nucleus accumbens shell.26 
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2.3.4 In Vivo Studies 
Linear regression analysis was performed to test the existence of a statistically 
significant linearity for the calibration curves. Changes in concentration of Glu 
and GABA were expressed as percent of the basal concentration, measured before 
drug or vehicle administration. Data are given as mean ± SEM. Comparison 
between treated and control rats were achieved on percentage transformed data 
using analysis of variance (ANOVA) and post-hoc comparison by Tukey-Kramer 
test. The level of significance was set at P < 0.05 for all comparisons. 
 
2.3.4.1 Experiments on Anesthetized Rats 
The CE-LIF method developed was initially used for the study of carbamathione-
induced changes in GABA and in the brain of anesthetized rats. For this purpose 
200 mg/kg carbamathione was administered i.v. as a bolus dose and brain 
microdialysis samples were collected. The effect of carbamathione administration 
on basal levels of GABA and Glu in anesthetized rats is shown in figure 2.10. The 
basal concentrations of GABA and Glu in microdialysis samples from the brain 
nucleus accumbens were 83.5 ± 12.9 nmol/L and 1.06 ± 0.23 µmol/L, 
respectively. Basal Glu concentrations were significantly increased by 91% (P < 
0.05 Tukey-Kramer test) from the first 5 min fraction after carbamathione 
administration.  
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Figure 2.10 Simultaneous monitoring of GABA and Glu in microdialysis samples from 
the nucleus accumbens of anesthetized rat. 
White squares represent experiments with carbamathione administration (n = 5)  and black squares 
represent control experiments (n = 3). Carbamathione (200 mg/kg) was administered i.v. (black 
arrow). Data shown as percent (mean ± SEM) of baseline preceding administration of drug or 
vehicle. * represents P < 0.05 versus control (ANOVA, Tukey-Kramer test).  
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The increase in Glu concentration from basal levels continued over the next 2 h 
after carbamathione administration with a peak increase of 177% (P < 0.05 
Tukey-Kramer test) at the sixteenth fraction (i.e. + 80 min). Basal GABA 
concentrations were significantly increased by 44% (P < 0.05 Tukey-Kramer test) 
from the first fraction following carbamathione administration, but during the 
next 15 min were reduced by 46% (P < 0.05 Tukey-Kramer test). GABA 
concentrations continued to remain reduced over the next 2 h following 
carbamathione administration. The lowest concentration of GABA was obtained 
in the eighteenth fraction (i.e. + 90 min) where basal GABA concentrations were 
significantly reduced by 76% (P < 0.05 Tukey-Kramer test). 
 
Since carbamathione is also a primary amine and can be derivatized by NDA it 
was included in the CE-LIF analysis of brain samples. This allowed the clearance 
of carbamathione from the brain nucleus accumbens to be monitored. Figure 2.11 
shows concentration in brain microdialysis samples versus time profile for 
carbamathione after the i.v. administration of carbamathione (200 mg/kg, n = 5). 
Carbamathione concentrations increased to a peak at 10 min after administration 
and then proceeded to fall exponentially. The PK parameters of carbamathione in 
the brain nucleus accumbens are given in table 2.12.  
 
 
 86 
Figure 2.11 Carbamathione concentration versus time profile in anesthetized rats. 
Concentration of carbamathione in rat brain nucleus accumbens following carbamathione 
administration (200 mg/kg i.v., n = 5). Microdialysis samples were collected every 5 min. Data 
shown as concentration (mean ± SEM).  
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Table 2.12 Pharmacokinetic paramaters of carbamathione in anesthetized rats. 
Pharmacokinetic parameters of carbamathione in rat brain nucleus accumbens following 
carbamathione administration (200 mg/kg i.v., n = 5). Data expressed as mean ± SEM. 
 
Pharmacokinetic Parameters Carbamathione 
Cmax (µmol/L) 4.5 ± 1.1 
tmax (min) 7.5± 2.5 
t1/2 (min) 5.5 ± 0.7 
K elim (1/min) 0.13 ± 0.01 
AUC (µmol/L min) 166 ± 40 
 
Cmax = maximum concentration  
tmax = time to maximum concentration  
t1/2 = elimination half-life 
Kelim = elimination constant 
AUC = area under the dialysate concentration versus time profile 
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It is interesting to note that the half-life of carbamathione in the brain is only 5.5 ± 
0.7 min and carbamathione was undetectable in microdialysis samples from the 
brain at 45 min after administration. However, the changes to basal concentrations 
of GABA and Glu upon carbamathione administration were observed to last for 
over 2 h (see figure 2.10). This finding suggests that carbamathione may be 
broken down rapidly to produce more long lived metabolites that cause some of 
the more sustained changes from basal levels observed in GABA and Glu. 
Alternatively, carbamathione does not directly impact GABA and Glu, but 
initiates a process that continues after carbamathione is no longer detectable.  
 
2.3.4.2 Experiments on Awake Rats 
Although initial experiments were performed on anesthetized rats, it was 
important to establish the relationship between carbamathione and the amino acid 
neurotransmitters in awake animal experiments. It is well established that the 
anesthetic ketamine has an effect on Glu neurotransmission.21,29 Awake animal 
experiments allow the monitoring of brain neurotransmitters without the effects of 
the anesthesia. The same dose of carbamathione that was administered in the 
anesthetized animal experiments (200 mg/kg i.v.) was administered to the awake 
animals as a bolus dose and brain microdialysis samples were collected from the 
nucleus accumbens. The basal concentrations of GABA and Glu in microdialysis 
samples from the nucleus accumbens were 97.8 ± 16.4 nmol/L and 1.81 ± 0.19 
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µmol/L, respectively. The effect of carbamathione administration on basal levels 
of GABA and Glu in awake rats is shown in figure 2.13. Basal Glu concentrations 
were significantly increased by 84% (P < 0.05 Tukey-Kramer test) from the first 
fraction following carbamathione administration, but during the next 45 min were 
reduced by 44% (P < 0.05 Tukey-Kramer test). Glu concentrations continued to 
remain reduced over the next 70 min following carbamathione administration. 
The lowest concentration of Glu was obtained in the fourteenth fraction (i.e. + 70 
min) whereas basal Glu concentrations were significantly reduced by 34% (P < 
0.05 Tukey-Kramer test). Basal GABA concentrations were significantly 
increased by 23% (P < 0.05 Tukey-Kramer test) from the first fraction following 
carbamathione administration, but during the next 20 min were reduced by 53% 
(P < 0.05 Tukey-Kramer test). GABA concentrations continued to remain reduced 
over the next 110 min following carbamathione administration. The lowest 
concentration of GABA was obtained in the thirteenth fraction (i.e. + 65 min) 
where basal GABA concentrations were significantly reduced by 22% (P < 0.05 
Tukey-Kramer test).  
 
Figure 2.14 shows concentration in brain microdialysis samples versus time 
profile for carbamathione after the i.v. administration of carbamathione (200 
mg/kg, n = 5). Carbamathione concentrations increased to a peak at 10 min after 
administration and then proceeded to fall exponentially. 
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Figure 2.13 Simultaneous monitoring of GABA and Glu in microdialysis samples from 
the nucleus accumbens of awake rat. 
White squares represent experiments with carbamathione administration (n = 5)  and black squares 
represent control experiments (n = 3). Carbamathione (200 mg/kg) was administered i.v. (black 
arrow). Data shown as percent (mean ± SEM) of baseline preceding administration of drug or 
vehicle. * represents P < 0.05 versus control (ANOVA, Tukey-Kramer test). 
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Figure 2.14 Carbamathione concentration versus time profile in awake rats. 
Concentration of carbamathione in rat brain nucleus accumbens following carbamathione 
administration (200 mg/kg i.v., n = 5). Microdialysis samples were collected every 5 min. Data 
shown as concentration (mean ± SEM).  
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The PK parameters of carbamathione in brain nucleus accumbens are given in 
table 2.15. Again, it is important to note that the half-life of carbamathione in the 
brain nucleus accumbens is only 4.4 ± 0.6 min and carbamathione was 
undetectable in microdialysis samples from the brain nucleus accumbens at 35 
min after administration.  
 
The results obtained from administration of carbamathione in awake animals 
differ from those obtained from anesthetized animals. Some of these results are 
expected. For instance, the PK of carbamathione clearance is faster in awake 
animals than in anesthetized animals because the basal metabolic rate is higher in 
non-anesthetized animals. The clearance was determined from the elimination rate 
constant, Kelim, which was 0.13 ± 0.01 min-1 for anesthetized rats and 0.16 ± 0.02 
min-1 for awake rats. Since carbamathione is eliminated at a faster rate for the 
awake rats, these rats also displayed a shorter elimination half-life, t1/2 (4.4± 0.6 
min) than those determined for the anesthetized rats (5.5 ± 0.7 min).  
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Table 2.15 Pharmacokinetic paramaters of carbamathione in awake rats. 
Pharmacokinetic parameters of carbamathione in rat brain nucleus accumbens following 
carbamathione administration (200 mg/kg i.v., n = 5). Data expressed as mean ± SEM. 
 
Pharmacokinetic Parameters Carbamathione 
Cmax (µmol/L) 8.4  ± 2.1 
tmax (min) 7.5 ± 2.5 
t1/2 (min) 4.4 ± 0.6 
K elim (1/min) 0.16 ± 0.02 
AUC (µmol/L min) 242 ± 39 
 
Cmax = maximum concentration  
tmax = time to maximum concentration  
t1/2 = elimination half-life 
Kelim = elimination constant 
AUC = area under the dialysate concentration versus time profile 
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2.4 Discussion 
Administration of carbamathione was correlated to changes in GABA and Glu in 
anesthetized and awake rats. These changes differed slightly in the two cases.  
Basal GABA levels were significantly reduced after the administration of 
carbamathione in both awake and anesthetized rats. However, while Glu 
concentrations were significantly increased after the administration of 
carbamathione in anesthetized rats, basal Glu levels were only initially increased 
in awake rats. In awake rats, 20 min after the administration of carbamathione, 
concentrations of Glu were significantly reduced from basal levels. One 
explanation for this difference is the anesthesia (ketamine) used in the case of 
anesthetized rats.  
 
Ketamine is a known non-competitive glutamate NMDA antagonist and previous 
studies have shown that when a drug-induced glutamate receptor response was 
being measured, there was significant interference of ketamine with the NMDA 
glutamate receptor-mediated component of the response in anesthetized rats.29,30 
Another study demonstrated that ketamine produced an increase of Glu 
transmission between the prefrontal cortex and nucleus accumbens associated 
with an increase in extracellular Glu levels in the nucleus accumbens of rats.31 
These studies suggest that the presence of ketamine would alter the response 
 95 
observed in the form of an increase in Glu after the administration of 
carbamathione in anesthetized rats.  
 
It is interesting to note that carbamathione is also a partial NMDA antagonist and 
the increase in Glu from basal levels observed in awake animals can be correlated 
with the clearance of carbamathione in the brain nucleus accumbens.32 As 
previously discussed, the majority of carbamathione was eliminated from the 
brain at 40 min after drug administration. This suggests that the initial increase 
from basal Glu concentration after carbamathione administration in awake 
animals may be due to carbamathione and the subsequent decrease from basal Glu 
levels may be due to other metabolites of the drug or other processes that were 
triggered by carbamathione administration. The role of carbamathione as a partial 
NMDA antagonist is important since NMDA antagonists such as memantine have 
been shown to be effective in treating alcohol dependence.33 NMDA antagonists 
have also been shown to block cocaine-induced behavior.34,35 
 
2.5 Conclusions 
The work in this chapter showed the application of a CE-LIF method for the 
simultaneous detection of GABA, Glu and carbamathione in rat brain dialysate. 
The analytical method was validated and it exhibited good linearity, accuracy and 
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reproducibility with nanomolar detection limits. The inclusion of carbamathione 
in the analysis provided the added advantage of obtaining PK and PD data. The 
administration of carbamathione was correlated with changes in the brain 
neurotransmitter systems in both awake and anesthetized rats. Although this 
system has been demonstrated specifically for the determination of GABA and 
Glu, it can potentially be applied to any primary amine analyte in brain dialysate. 
By changing separation conditions, other amino acids could potentially be added 
to the analysis. Future studies will focus on the addition of dopamine to the 
present analysis because dopamine has been shown to be one of the 
neurotransmitters involved in the pathways associated with addiction.36,37 In 
addition, studies to determine the metabolites of carbamathione will also be 
carried out since the effect on the GABA, Glu and DA systems appears to 
continue even when carbamathione has been cleared from the brain.  
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3 IN VIVO MICRODIALYSIS AND MEKC-LIF FOR MONITORING 
GABA, GLUTAMATE, DOPAMINE, AND CARBAMATHIONE 
3.1 Introduction 
In the previous chapter describes the development of a capillary electrophoresis 
coupled with laser-induced fluorescence (CE-LIF) method to detect gamma-
amino butyric acid (GABA), glutamate (Glu), and carbamathione in microdialysis 
samples from the brain nucleus accumbens. However, the method in the analysis 
did not include dopamine (DA), which has been shown to be a key 
neurotransmitter in alcohol and cocaine addiction. In addition, microdialysis 
samples were only collected from the brain. In order to determine the 
pharmacokinetics (PK) and pharmacodynamics (PD) of carbamathione, it was 
important to obtain microdialysis samples from the plasma, particularly after the 
intravenous (i.v.) administration of the drug. These samples would then have to be 
analyzed to detect and quantify carbamathione. The following chapter describes a 
micellar electrokinetic chromatography coupled with laser-induced fluorescence 
(MEKC-LIF) method that was developed to achieve these goals. 
 
3.1.1 Background and Significance 
One of the first steps in the development of carbamathione as a possible 
pharmacotherapeutic agent in either alcohol and/or cocaine addiction is 
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characterizing its effects on various neurotransmitters in vivo. Evidence in the 
literature suggests that the dopaminergic, glutamatergic, and GABAergic systems 
play an important role in addiction.1 Therefore, it is of interest to study the effect 
of carbamathione on these neurotransmitters in a time-dependent and dose-
dependent manner. Microdialysis provides an ideal tool for studying the PD of 
carbamathione in a specific brain region. The use of a fluorescence detection 
scheme provides the selectivity and sensitivity necessary in such studies. MEKC 
in combination with LIF provides a highly sensitive method for the measurement 
of GABA, Glu, and DA in microdialysis samples.2-5  
 
3.1.2 Specific Aims of Research 
The goal of this research was to apply an MEKC separation method to determine 
the changes in the GABA, Glu, and DA from the nucleus accumbens and 
prefrontal cortex of a rat brain as related to the administration of carbamathione. 
An existing MEKC-LIF separation method was modified and optimized in order 
to include carbamathione in the analysis of GABA, Glu, and DA in the 
microdialysis samples.4 An liquid chromatography-tandem mass spectrometric 
(LC-MS/MS) method was used to determine the concentration of carbamathione 
in plasma microdialysis samples.6 The MEKC-LIF method was not suitable for 
the analysis of plasma microdialysis samples because the derivatized plasma 
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dialysate displayed several endogenous peaks. Carbamathione could not be 
sufficiently resolved from these endogenous peaks. In addition, the LC-MS/MS 
method was specific for carbamathione, which was the only analyte of interest in 
the plasma. The determination of the concentration of carbamathione in plasma 
dialysate was necessary in monitoring carbamathione PK. The limits of detection 
and quantification for both the MEKC-LIF and LC-MS/MS methods satisfied the 
analytical requirements of this study based on the expected concentration ranges 
for the analytes of interest. The expected concentration range for GABA, Glu and 
dopamine in microdialysis samples from rat brain are 40-100 nmol/L, 0.7-2.5 
µmol/L and 1-15 nmol/L, respectively.4,5,7-9 Previous studies with carbamathione 
have demonstrated that micromolar concentrations of carbamathione were 
detected in rat brain dialysate after a 200 mg/kg dose of carbamathione.10 The 
temporal resolution achieved for this method was initially 5 min and later reduced 
to 3 min to obtain additional PK and PD data. The neurotransmitter and 
carbamathione data was used to establish PK and PD relationships between the 
administration of various doses of the drug and changes observed in the 
neurotransmitter systems.  
 
 107 
3.2 Experimental 
3.2.1 Chemicals and Reagents 
In addition to the chemicals listed in Chapter 2 (2.2.1 Chemicals and Reagents), 
several other chemicals were purchased for these studies. Dopamine (DA), 2-
aminobutyric acid (2-ABA), s-hexylglutathione (SGSH), lithium tetraborate 
(LTB), and lithium dodecylsulfate (LDS) were purchased from Sigma (St. Louis, 
MO, USA).  Ammonium formate and formic acid were purchased from Fisher 
Scientific (Pittsburgh, PA, USA). Ultrapure water was obtained with a Milli-Q 
system (Millipore, Bedford, MA, USA) and a WaterPro Plus water purification 
system (18 MΩ/cm) (Labconco, Kansas City, MO, USA). Carbamathione was 
synthesized using methods previously developed.11,12  
 
Ringer’s solution, which was used as perfusate for the vascular microdialysis 
probes, consisted of 145 mmol/L sodium chloride, 2.7 mmol/L potassium 
chloride, 1.0 mmol/L magnesium chloride, and 1.2 mmol/L calcium chloride. The 
Ringer’s solution was filtered through a 0.2 µm pore size cellulose acetate 
membrane filter and stored at room temperature (25° C). Artificial cerebrospinal 
fluid (aCSF) was prepared as described in Chapter 2 (2.2.1 Chemicals and 
Reagents). SGSH was prepared as a 1 mmol/L stock solution in 1 mol/L of 
ammonium hydroxide.  
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Standard solutions of amino acids (1 mmol/L each) were dissolved in 0.1 mol/L 
perchloric acid and stored at 4° C. A stock solution of 1 mmol/L carbamathione 
(molecular weight [M.W.] 406 g/mol) was prepared in 10 mmol/L ammonium 
formate. Carbamathione calibration standards were prepared by serially diluting 
the carbamathione stock solution with aCSF or Ringer’s. 
 
The background electrolyte (BGE) consisted of 22.5 mmol/L LTB (pH 9.2) and 
20 mmol/L LDS. The borate buffer for derivatization was prepared as described 
in Chapter 2 (2.2.1 Chemicals and Reagents). The derivatization reaction was 
carried out as described in Chapter 2 (2.2.2 Derivatization). 
 
3.2.2 MEKC-LIF Instrumentation 
The electrophoretic system consisted of an automatic P/ACE MDQ system 
(Beckman-Coulter, Fullerton, CA, USA) equipped with an external LIF detector 
(ZETALIF, Picometrics, Toulouse, France). The excitation was performed by a 
diode pumped solid-state laser (CrystaLaser, Reno, NV, USA) at a wavelength of 
442 nm. A 50 µm id fused-silica capillary (Polymicro Technology, Phoenix, AZ, 
USA) was used (65 cm total length, 50 cm effective), with a separation voltage of 
10 kV for 10 min and 20 kV for 8 min (a two-step separation). Each day, before 
the analyses were performed, the capillary was sequentially flushed at 20 psi with 
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methanol (MeOH) for 5 min, ultrapure water for 2 min, 1 mol/L hydrochloric acid 
for 5 min, ultrapure water for 2 min, 1 mol/L sodium hydroxide (NaOH) for 10 
min, ultrapure water for 2 min and finally with the BGE for 5 min. Between 
analyses, the capillary was flushed at 20 psi with 1 mol/L NaOH for 3 min, with 
ultrapure water for 3 min and then with the BGE for 3 min. All the solutions 
injected onto the capillary were sterilized using a disposable 0.22 m 
polyethersulfone (PES) membrane syringe filter (Millipore, Co. Cork, Ireland). 
Samples were introduced onto the capillary by hydrodynamic injections for 15 s 
at 0.7 psi. Electropherograms were acquired on Beckman 32 Karat software.  
 
3.2.3 MEKC-LIF Method Development  
The method used in this work was based on a previously reported method that 
was developed for the separation of several amino acids and catecholamines 
labeled with naphthalene-2,3-dicarboxyaldehyde (NDA) in microdialysis 
samples.4 Under the conditions reported, it was possible to separate most of the 
analytes of interest. However, carbamathione and the internal standard (IS, 2-
ABA) were not very well resolved. The effect of varying the capillary 
temperature was evaluated to achieve optimum resolution.  Decreasing the 
temperature resulted in increased resolution and migration times (figure 3.1).  
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Figure 3.1 Effect of varying temperature on separation by MEKC-LIF. 
Effect of temperature on separation of NDA-derivatized carbamathione (1), GABA (3), and Glu 
(4). IS (2) was 2-ABA. Electropherograms were obtained using 22.5 mmol/L LTB and 20 mmol/L 
LDS BGE and a two-step separation voltage (10 kV for 10 min and 20 kV for 8 min). NDA-
derivatized compounds were detected using LIF detection (ex. 442 nm). 
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Temperatures between 15-25° C were tested and the best separation was obtained 
at 15° C. The resolution data at this temperature indicated good separation 
between standards (R > 1.5) for all pairs tested.  
 
The generation of absorbance by NDA-labeled GABA, Glu, DA, and 
carbamathione as a function of time was tested to determine the optimum 
derivatization time. The results of this study are shown in figure 3.2. Samples 
were derivatized with NDA and were injected onto the CE system after 2.5 to 30 
min. The plateaus are different for the different amino acids indicating the 
difference in absorbance of each of these molecules. The optimum derivatization 
time for GABA, Glu, DA and carbamathione was determined to be 5 min since 
maximum absorptions were reached at that time point (figure 3.2).  
 
Peak identification in microdialysis samples were carried out by comparing 
migration times with those present in standards (figure 3.3). In addition, the 
observed height of the peaks of interest increased when exogenous Glu, GABA, 
and DA were added to the microdialysis samples. No additional peaks appeared 
when Glu, GABA and DA were added. Background peaks associated with NDA 
derivatization did not interfere with any of the analytes of interest.  
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Figure 3.2 Generation of absorbance at 442 nm as a function of time for GABA, Glu, 
DA, and carbamathione. 
GABA, Glu, DA, and carbamathione (10 µmol/L) were derivatized with NDA and injected after 
2.5 -30 min.  
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Figure 3.3 Typical MEKC-LIF electropherograms. 
Electropherograms of standard solution (A) containing carbamathione (1), GABA (3), Glu (4), and 
DA (5) compared to dialysate obtained from rat brain (B).  IS (2) was 2-ABA. Electropherograms 
were obtained using 22.5 mmol/L LTB and 20 mmol/L LDS BGE and a two-step separation 
voltage (10 kV for 10 min and 20 kV for 8 min). NDA-derivatized compounds were detected 
using LIF detection (ex. 442 nm). 
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3.2.4 MEKC-LIF Method Validation Experiments 
Calibration standards for method validation contained GABA prepared in a 
concentration range of 10-9- 10-6 mol/L, Glu in a range of 10-9- 10-6 mol/L, DA in 
a range of 10-10- 10-7 mol/L, and carbamathione prepared in a range 10-8- 10-5 
mol/L. Calibration plots were plotted as the ratio of the area of compound of 
interest to area of the internal standard versus concentration (number of 
concentrations of each analyte, n = 5). The limits of detection and quantification 
were calculated as the analyte concentration that resulted in peaks with signal-to-
noise ratio (S/N) of 3 and 10 respectively. Intra-day and inter-day reproducibility 
were determined using standards of Glu, GABA, DA, and carbamathione 
prepared in aCSF and microdialysis samples. The accuracy of the method was 
calculated from the analysis of standards in aCSF, microdialysis samples, and 
microdialysis samples spiked with known concentrations of standards (in 
triplicate). 
 
3.2.5 LC-MS/MS Instrumentation 
The chromatographic separations were performed on an Alltech Altima C-18 (50 
mm x 2.1 mm i.d., 3 µm particles) analytical column (Alltech Associates, Inc, 
Deerfield, Illinois, USA) at a flow rate of 0.3 mL/min with analysis time of 35 
min. Solvent A consisted of 10 mmol/L ammonium formate, MeOH and formic 
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acid (99:1:0.06, v/v/v). Solvent B consisted of MeOH, 10 mmol/L ammonium 
formate and formic acid (99:1:0.06, v/v/v). The chromatograph consisted of a 20 
min linear gradient from 95% aqueous to 95% organic followed by a 15 min re-
equilibration. Five microliters of IS (5 nmol/L) was added to 5 µL of the 
calibration standard sample and vortexed. This mixture was then diluted with 40 
µL of water and injected onto the LC column directly. Tandem mass spectra were 
acquired on a Quattro Ultima “triple” quadrupole instrument (Micromass Ltd. 
Manchester UK.). The electrospray source block was 80° C and probe desolvation 
temperature was 200° C.  Argon collision gas was set to attenuate the beam by 
15% (2e-3 mbar on a gauge near the collision cell).  The cone voltage was 35 V. 
Quadrupoles 1 and 3 were tuned to a resolution of 0.9 atomic mass units full 
width at half height. Mass spectrometric analysis was conducted in positive ion 
mode and set-up in selected reaction monitoring (SRM) mode. Data processing 
was performed on MassLynx version 4.1 software. 
 
3.2.6 LC-MS/MS Method Development  
SGSH was selected as the IS since it was a non-endogenous glutathione adduct. 
SRM acquisitions were used for sensitivity and extended dynamic range. The 
SRM of three transitions were recorded: m/z = 100 and m/z = 175 as products of 
m/z = 407.4 at 25 eV CE ([M + H]+ carbamathione) and m/z = 263 as the product 
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of m/z = 392.4 at 10 eV CE ([M + H]+ SGSH) (figure 3.4). Quantification of 
carbamathione was based on the sum of the integrations of the SRM traces from 
the two product ions.  
 
The post-column infusion method was used to provide a qualitative assessment of 
matrix effects and to identify chromatographic regions most likely to experience 
matrix effects. Briefly, an infusion pump was used to deliver a constant amount of 
carbamathione into the LC stream entering the ion source of the mass 
spectrometer. The mass spectrometer was run in SRM mode to follow the infused 
analyte. Blank dialysate was then injected on the LC column. Any endogenous 
compound that eluted from the column would cause a variation in electrospray 
ionization response of carbamathione. Matrix effects were also assessed by 
comparison of standards in Ringer’s and in water at three concentrations (5.0 x 
10-9, 1.0  x 10-7 and 5.0 x 10-6 mol/L). The post-column infusion of 1 µmol/L 
carbamathione challenged by the injection of blank dialysate demonstrated no 
significant matrix interference. The comparison of standards prepared in Ringer’s 
and in water supported this assessment since there was no significant difference in 
the SRM peak areas. 
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Figure 3.4 Tandem mass spectrum of carbamathione after activation of [M+H]+ at 25 
eV CE. 
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The selectivity of the method was tested by analyzing drug-free plasma dialysate. 
Each dialysate sample was tested using the LC-MS/MS conditions described to 
ensure no interference with carbamathione and the IS. No other endogenous peaks 
were observed (figure 3.5). 
 
3.2.7 LC-MS/MS Method Validation Experiments 
The intra-day accuracy and precision were calculated by analyzing five replicates 
of Ringer’s solution containing carbamathione at three concentrations: 5.0 x 10-9, 
1.0 x 10-7 and 5.0 x 10-6 nmol/L. The inter-day accuracy and precision were 
determined by analyzing the three concentrations on five different runs.  
 
3.2.8 Microdialysis 
3.2.8.1 Brain and Vascular Probes 
Microdialysis samples were obtained from the brain utilizing microdialysis probes 
(CMA 12 Elite) with 2 mm membranes purchased from CMA Microdialysis 
(North Chelmsford, MA, USA). The vascular probes were fabricated in-house.13 
 
 
 
Figure 3.
Chromatograms of plasma microdialysis sam
carbamathione and IS (SGSH). Chromatograms were acquired in SRM mode. 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 Typical LC-MS/MS chromatograms.  
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Fused silica tubing, 75 µm i.d. and 150 µm o.d. (Polymicro Technologies Inc., 
Phoenix, AZ, USA) was inserted into a 10 mm MicroRenathane surgical tubing 
(MRE-033), 356 µm i.d. and 838 µm o.d. (Braintree Scientific, Braintree, MA, 
USA), so that a 10 mm length is exposed. The exposed silica was then fed into a 
piece of regenerated cellulose dialysis fiber (AN69® HF membrane) with a 240 
µm i.d., 50-µm wall thickness and 5 kDa molecular weight cutoff (Hospal 
Industrie, Meyzieu, France). This membrane was also fed into the MRE-033 and 
threaded one-third of the way up. The end of the membrane was cut and sealed 
with ultraviolet (UV) glue (UVEXS, Sunnyville, CA). The UV glue was activated 
under a UV light system ELC-450 (Electro-Lite Corporation, Danbury, CT, 
USA), with 5.0 W/cm2 and at 365 nm for five seconds. The membrane was 
secured to the MRE-033 with UV glue. A small piece of plastic mesh was secured 
with UV glue just above the MRE-033 for the purpose of securing the probe once 
implanted. The probe was completed by feeding a necessary length of 
polyethylene tubing (PE-50), 580 µm i.d. and 965 µm o.d. (Fisher Scientific, 
Pittsburgh, PA), over the two free silica pieces and UV glued into place. The 
relative recovery of carbamathione through the microdialysis probes were 
estimated by delivery experiments.14 Delivery experiments were carried out by 
perfusing 1 µmol/L of carbamathione through the microdialysis probes in vivo at 
2 µL/min, and determining the percentage that diffused through the membrane. 
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3.2.8.2 Animals and Surgery 
All awake experiments were carried out in accordance with the Institutional 
Animal Care and Use Committee (IACUC) animal protocols as described in 
Chapter 2 (2.2.6.2 Animals and Surgery). Sterile surgeries were conducted since 
all the experiments in this study involved awake animals. The microdialysis 
probes and surgical instruments were sterilized by ethylene oxide. The initial 
anesthesia and preparation of the incision sites are described in detail in Chapter 2 
(2.2.6.2 Animals and Surgery).  
 
The femoral vein of the rat was cannulated for i.v. dosing as described in Chapter 
2 (2.2.6.2 Animals and Surgery). The femoral cannula was externalized through a 
sterile incision in the neck. All incisions were closed with stitches or surgical 
staples. 
 
The jugular vein of the rat was isolated by making an incision over the right 
shoulder of the rat and carefully pulling the fat and tissue out of the way. Once 
isolated, a small nick was made in the vein with spring scissors held almost 
perpendicular to the vein. The vascular probe was then inserted into the vein to 
the vena cava. The jugular was tied above and below the probe to hold the probe 
in place. The probe tubing was tunneled under the skin and externalized through a 
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sterile incision in the neck. The jugular incision was closed with surgical staples 
or sutures. 
 
The brain probes were implanted as previously described.6 The coordinates of the 
insertion sites relative to the bregma line were +1.5 mm anterior, +0.9 mm lateral 
and −6.2 mm ventral for the nucleus accumbens shell and +3.7 mm anterior, +0.7 
mm lateral and −1.0 mm ventral for the prefrontal cortex, according to the rat 
stereotaxic atlas.15 Holes 1 mm in diameter were drilled through the skull at the 
insertion sites and intracerebral guide cannulas were lowered into the specified 
regions using a micromanipulator attached to the stereotaxic apparatus.  The guide 
cannulas were positioned 2 mm above the specified regions and then affixed to 
the skull with dental cement. The dummy probe in the guide cannula was replaced 
with the CMA microdialysis probes.  
 
After the surgical procedures, the rats were administered 0.5 to 3 mL/kg of saline 
subcutaneously (s.c.) to prevent dehydration. During recovery from anesthesia, 
the rats were placed in a rat turn equipped with a swivel arm (Bioanalytical 
Systems Inc., West Lafayette, IN, USA). A heating pad was placed under the rats 
to provide warmth during the recovery from anesthesia.   
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3.2.8.3 Microdialysis Sample Collection 
Microdialysis samples were collected using a CMA 100 microinfusion pump and 
a HoneyComb fraction collector (Bioanalytical Systems Inc., West Lafayette, IN, 
USA). Connection of the microinjection pump and the fraction collector to the 
microdialysis probes was accomplished with tubing connectors (Bioanalytical 
Systems Inc., West Lafayette, IN, USA). After implantation, the brain probes and 
the vascular probes were perfused with aCSF and Ringer’s solution, respectively, 
at 2 µL/min. The dead volume between the dialysis site and the fraction collector 
was also determined in order to accurately monitor the neurochemical changes. 
The CMA 12 Elite 2 mm brain probes had a reported outlet internal volume of 3 
µL. The fluorinated ethylene propylene (FEP) tubing used to connect the syringe 
to the probes and the probes to the fraction collector had an internal volume of 
0.12 µL/cm length. The delay was estimated to be 405 s and upon the 
administration of carbamathione, microdialysis samples were collected after this 
period of time.  
 
3.2.8.4 In Vivo Experiments 
3.2.8.4.1 Administration of 200 mg/kg Carbamathione 
The collection of 5 min samples was initiated after a 24 h waiting period for 
awake experiments. For dosing purposes, the carbamathione dose (200 mg/kg) 
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was prepared by adding a few drops of 1 mol/L sodium bicarbonate solution and 
bringing the volume up to 1 mL with saline solution. After the i.v. administration 
of carbamathione through the femoral cannula, microdialysis samples were 
collected for 3 h. At the end of the experiments, the rats were sacrificed by 
placement in an isofluorane chamber for approximately 30 min. Rat brains were 
harvested in order to perform a histological confirmation of brain probe position.  
 
3.2.8.4.2 Increased Temporal Resolution for Carbamathione Dose-Response 
The collection of 3 min samples was initiated after a 24 h waiting period for 
awake experiments. After the i.v. administration of carbamathione (200 mg/kg, 50 
mg/kg, and 20 mg/kg) through the femoral cannula, microdialysis samples were 
collected for three hours. At the end of the experiments, the rats were sacrificed 
by placement in an isofluorane chamber for approximately thirty minutes. Rat 
brains were harvested in order to perform a histological confirmation of brain 
probe position. 
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3.3 Results and Discussion 
3.3.1 MEKC-LIF Method Validation Results 
Validation was carried out in accordance with instructions for good laboratory 
practice.16,17 Validation parameters were determined for GABA, Glu, and 
carbamathione in standards as well as brain microdialysis samples. The final 
results are shown in table 3.6. The regression coefficient of the calibration 
obtained with standard solutions and microdialysis samples showed good linearity 
and led to the routine use of only three points of the calibration curve. Limits of 
detection and quantification were lower than concentrations measured in 
microdialysis samples from the brain.  
 
3.3.2 LC-MS/MS Method Validation Results 
The carbamathione calibration curve was constructed by plotting the peak area 
ratio of carbamathione to the IS versus the concentration of carbamathione. The 
calibration curve was characterized by two different linear segments. The 
regression coefficient of the calibration showed good linearity (r2 = 0.9987 over 
the range of 0.25-100 nmol/L and r2 = 0.9993 over the range of 0.5-250 µmol/L). 
Figure 3.7 displays representative calibration curves for the low and high 
concentration ranges. 
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Table 3.6 Quantitative parameters for the analysis GABA, Glu, DA, and 
carbamathione in aCSF and microdialysis samples by MEKC-LIF. 
 
 aCSF GABA Glu DA Carb 
Calibration Range (mol/L) 10-9-10-6 10-9-10-6 10-10-10-7 10-8-10-5 
Regression Coefficient of Calibration 
(r²) 0.9985 0.9990 0.9942 0.9991 
Intra-assay repeatability (%RSD)a 8.3 7.1 8.9 6.5 
Intra-day repeatability (%RSD)a 5.7 6.0 4.7 3.7 
Inter-day repeatability (%RSD)b 7.2 3.5 4.2 4.9 
Accuracy (%)c 3.2-1.8 2.9-1.4 3.3-2.0 3.6-1.8 
Limits of Detection (mol/L) 1.5 x 10-9 6.0 x 10-10 5.0 x 10-10 1.0 x 10-9 
Limits of Quantification (mol/L) 6.0 x 10-9 3.0 x 10-9 2.5 x 10-9 5.0 x 10-9 
 Microdialysis Samples GABA Glu DA Carb 
Calibration Range (mol/L)d 10-9-10-6 10-9-10-6 10-10-10-7 10-8-10-5 
Regression Coefficient of Calibration 
(r²) 0.9967 0.9974 0.9905 0.9980 
Intra-assay repeatability (%RSD)a 10.4 8.5 11.2 7.3 
Intra-day repeatability (%RSD)a 8.2 7.5 8.3 6.1 
Inter-day repeatability (%RSD)b 9.4 5.9 10.1 6.0 
Accuracy (%)c,d 9.3-6.5 4.8-2.4 10.9-7.6 4.0-2.1 
 
a. Five replicates 
b. Five days, three replicates each 
c. Three replicates, tested concentrations of 10-7- 10-8 mol/L for GABA, Glu, DA and 
carbamathione 
d. Spiked microdialysis samples  
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Figure 3.7 Representative calibration curves for LC-MS/MS method. 
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Since the LC-MS/MS method was used to detect carbamathione in plasma 
dialysate samples and these samples contained micromolar concentrations of 
carbamathione, the high concentration range calibration curve was used. The 
lowest limit of detection was estimated as the amount of carbamathione that 
resulted in a signal three times the noise (S/N ≥ 3) and was calculated to be 0.25 
nmol/L. The lowest limit of quantification with acceptable accuracy and precision 
(<10%) was 1 nmol/L. 
 
Intra-day accuracy and precision were determined by analyzing five replicates at 
three different concentration levels.  Inter-day accuracy and precision were 
determined by analyzing samples at the three concentration levels, five times at 
each concentration. The final results are shown in table 3.8.  
 
3.3.3 Microdialysis Probe Calibration 
The characteristics of the implanted microdialysis probes were evaluated at the 
end of each experiment. Based on the delivery experiments, the in vivo extraction 
efficiency by delivery (EEd) (mean ± standard error of mean [SEM], n = 3) for 
carbamathione was determined to be 25.8 ± 4.1% for the brain probes and 57.5 ± 
10.4% for the plasma vascular probes. 
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Table 3.8 Quantitative parameters for the analysis of carbamathione in Ringer’s 
solution by LC-MS/MS 
Samples were analyzed at the three concentration levels, five times at each concentration. 
 
Concentration (mol/L) RSD (%) 
Nominal Mean Measured  Intra-day Inter-day 
5.0 x 10-9 4.78 x 10-9 4.7 7.2 
1.0 x 10-7 1.04 x 10-7 2.2 4.3 
5.0 x 10-6 4.92 x 10-6 3.1 3.8 
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The concentrations of carbamathione determined in the microdialysis samples 
were corrected for the EEd of the probe used. The in vitro extraction efficiency by 
recovery (EEr) (mean ± SEM, n = 3) for GABA, Glu and DA was estimated to be 
17.2 ± 1.8%, 13.5 ± 1.4% and 14.1 ± 1.9% respectively.  The concentrations of 
GABA, Glu and DA were expressed as percent (mean ± SEM) of baseline 
concentrations in order to monitor changes from basal levels upon administration 
of carbamathione.  
 
3.3.4 Histological Confirmation of Brain Probe Position 
Microdialysis probe locations were examined histologically after completion of 
the experiments. After the rats were euthanized by isofluorane inhalation, the 
brains were removed and fixed in buffered formalin (10%). After localization of 
the microdialysis probes, the brain was sliced transversely in the coronal plane. 
Samples were taken from the prefrontal cortex and the nucleus accumbens. The 
tissues were embedded in paraffin wax and the sections cut at 5 µm and stained 
with hematoxylin-eosin. The sections were then examined by standard light 
microscopy. Only probes with at least 85% of the active dialysis membrane in the 
nucleus accumbens shell or prefrontal cortex were included in the study. The 
representative locations of microdialysis probes in the nucleus accumbens and 
prefrontal cortex are shown in figure 3.9. 
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Figure 3.9 Representative locations of microdialysis probes in nucleus accumbens shell 
and prefrontal cortex. 
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3.3.5 In Vivo Studies 
3.3.5.1 Administration of 200 mg/kg Carbamathione and 5 min Sampling 
Interval 
Changes in concentration of Glu, GABA, and DA were expressed as percent of 
the basal concentration, measured before drug or vehicle administration.  An 
MEKC-LIF method was developed to measure the carbamathione-induced 
changes in GABA, Glu and DA and in the rat brain. For this purpose a 200 mg/kg 
dose of carbamathione was administered as an i.v. bolus dose and brain and 
plasma microdialysis samples were collected every 5 min. Comparison between 
treated and control rats were achieved on percentage transformed data using 
analysis of variance (ANOVA) and post-hoc comparison by Tukey-Kramer test. 
The level of significance was set at P < 0.05 for all comparisons. Data are 
reported as percentages of baseline and mean ± SEM. 
 
The effect of carbamathione administration (200 mg/kg) on basal levels of 
GABA, Glu, and DA in the nucleus accumbens of rats is shown in figure 3.10. 
The basal concentrations of GABA, Glu, and DA in microdialysis samples from 
the nucleus accumbens were 63.5 ± 11.7 nmol/L, 2.9 ± 0.5 µmol/L, and 7.4 ± 1.8 
nmol/L, respectively.  
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Figure 3.10 GABA, Glu, and DA in nucleus accumbens after a 200 mg/kg dose of 
carbamathione and 5 min sampling interval. 
White squares represent experiments (n = 3) and black squares represent controls (n = 3).  0 min 
indicates time point of carbamathione administration (200mg/kg i.v.). * represents P < 0.05 versus 
control (ANOVA, Tukey-Kramer test). 
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Basal GABA concentrations were significantly decreased by 28% (P < 0.05 
Tukey-Kramer test) in the first fraction following carbamathione administration 
and continued to remain reduced over the next 2 h following carbamathione 
administration. The lowest concentration of GABA was obtained in the eleventh 
fraction (i.e. + 55 min) where basal GABA concentrations were significantly 
reduced by 74% (P < 0.05 Tukey-Kramer test).  
 
Basal Glu concentrations were significantly increased by 78% (P < 0.05 Tukey-
Kramer test) in the first 5 min fraction after carbamathione administration. The 
increase in Glu concentration from basal levels continued over the next 30 min 
after carbamathione administration with a peak increase of 133% (P < 0.05 
Tukey-Kramer test) at the third fraction (i.e. + 15 min). However, during the next 
10 min Glu concentration was reduced by 32% (P < 0.05 Tukey-Kramer test) and 
continued to remain reduced over the next 95 min. The lowest concentration of 
Glu was obtained in the sixteenth fraction (i.e. + 80 min) where basal Glu 
concentrations were significantly reduced by 84% (P < 0.05 Tukey-Kramer test).  
 
Basal DA concentrations were significantly increased by 480% (P < 0.05 Tukey-
Kramer test) in the first fraction following carbamathione administration, and 
continued to remain increased over the next 2 h.  
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The effect carbamathione administration (200 mg/kg) on basal levels of GABA, 
Glu, and DA in the prefrontal cortex of rats is shown in figure 3.11. The basal 
concentrations of GABA, Glu, and DA in microdialysis samples from the 
prefrontal cortex were 49.8 ± 8.4 nmol/L, 2.4 ± 0.3 µmol/L, and 3.8 ± 0.5 nmol/L, 
respectively.  
 
Basal GABA concentrations were significantly decreased by 5% (P < 0.05 Tukey-
Kramer test) in the first fraction following carbamathione administration. The 
GABA levels continued to remain reduced over the next 2 h following 
carbamathione administration. The lowest concentration of GABA was obtained 
in the ninth fraction (i.e. + 45 min) where basal GABA concentrations were 
significantly reduced by 62% (P < 0.05 Tukey-Kramer test).  
 
Basal Glu concentrations were significantly increased by 113% (P < 0.05 Tukey-
Kramer test) in the first 5 min fraction after carbamathione administration. The 
increase in Glu concentration from basal levels continued over the next 10 min 
after carbamathione administration. However, during the next 5 min Glu 
concentration was reduced by 23% (P < 0.05 Tukey-Kramer test) and continued 
to remain reduced over the next 80 min. The lowest concentration of Glu was 
obtained in the tenth fraction (i.e. + 50 min) where basal Glu concentrations were 
significantly reduced by 60% (P < 0.05 Tukey-Kramer test). 
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Figure 3.11 GABA, Glu, and DA in prefrontal cortex after a 200 mg/kg dose of 
carbamathione and 5 min sampling interval. 
White squares represent experiments (n = 3) and black squares represent controls (n = 3).  0 min 
indicates time point of carbamathione administration (200mg/kg i.v.). * represents P < 0.05 versus 
control (ANOVA, Tukey-Kramer test). 
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Basal DA concentrations were significantly increased by 32% (P < 0.05 Tukey-
Kramer test) in the first fraction following carbamathione administration, and 
continued to remain increased over the next 2 h. The highest concentration of DA 
was obtained in the ninth fraction (i.e. + 45 min) where basal DA concentrations 
were significantly reduced by 250% (P < 0.05 Tukey-Kramer test). 
 
Figure 3.12 shows concentration in brain microdialysis samples and plasma 
microdialysis samples versus time profile for carbamathione after administration 
of carbamathione (200 mg/kg i.v., n = 3). Carbamathione concentrations in the 
plasma and the brain increased to a peak at 5 and 10 min, respectively after 
administration and then proceeded to fall exponentially. The pharmacokinetic 
parameters of carbamathione in brain are given in table 3.13. The elimination 
constants for carbamathione in the brain and plasma are very close in value which 
suggests passive diffusion across the blood-brain barrier. It is also important to 
note that the half-lives of carbamathione in the plasma, prefrontal cortex and 
nucleus accumbens are 4.81 ± 0.97, 4.31 ± 0.59 and 4.19 ± 0.66 min respectively. 
The sample collection time of 5 min was more than the estimated half-lives of 
carbamathione. This suggests that the collection time may have to be decreased in 
order to obtain the relevant PK and PD data on carbamathione. 
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Figure 3.12 Carbamathione concentration versus time profile after 200 mg/kg dose of 
carbamathione and 5 min sampling interval. 
Concentration of carbamathione in rat brain following carbamathione administration (200 mg/kg 
i.v., n = 3). Microdialysis samples were collected every 5 min. Data shown as concentration (mean 
± SEM).  
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Table 3.13 Pharmacokinetic paramaters of carbamathione with 5 min sampling 
interval. 
Pharmacokinetic parameters of carbamathione in rat brain following carbamathione administration 
(200 mg/kg i.v., n = 3) and 5 min sample collection. Data expressed as mean ± SEM. 
 
200 mg/kg  Cmax  tmax t1/2 Kelim AUC 
PFC  20.4 ± 3.6  7.5± 2.5 4.31 ± 0.59 0.16 ± 0.02 252 ± 81 
NAc  25.8 ± 4.1 7.5± 2.5 4.19 ± 0.66 0.17 ± 0.02 308 ± 87 
Plasma  213 ± 37 2.5± 2.5 4.81 ± 0.97 0.15 ± 0.03  2310 ± 628 
 
PFC= Prefrontal Cortex 
NAc=Nucleus Accumbens 
Cmax = maximum concentration (µmol/L) 
tmax = time to maximum concentration (min) 
t1/2 = elimination half-life (min) 
Kelim = elimination constant (1/min) 
AUC = area under the dialysate concentration versus time profile (µmol/L min) 
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3.3.5.2 Increased Temporal Resolution for Carbamathione Dose-Response 
The MEKC-LIF method developed was applied to a 200 mg/kg i.v. dose of 
carbamathione followed by a 5 min sample collection interval. The sampling rate 
was later increased to 3 min sample collections to obtain important PK and PD 
data related with three doses (200 mg/kg, 50 mg/ kg, and 20 mg/kg i.v.) of 
carbamathione. Data are given as mean ± SEM. Two-way ANOVA with repeated 
measures over time was used to compare neurotransmitter levels between 
treatments and within treatments over time. Post hoc comparisons were made 
using Fisher's least significant difference (LSD) test. The level of significance 
was set as at least P < 0.05 for all comparisons. 
 
Figure 3.14 shows the effect of three doses of carbamathione (200 mg/kg, 50 
mg/kg, and 20 mg/kg i.v.) on basal GABA levels in the nucleus accumbens. 
Carbamathione produced a significant decrease (19%-40%, P < 0.05) in 
extracellular basal GABA concentrations 6-12 min after dosing and remained 
decreased for the next 80-96 min. The lowest concentrations (23%-77%, P < 
0.05) were obtained 45-63 min after dosing. Two-way ANOVA for repeated 
measures over time for the data shown in figure 3.14 revealed a significant main 
effect of treatment (F3,47 = 21.37, P < 0.05), a significant interaction between 
treatment and time interaction (F45,705 = 9.13, P < 0.05), and a trend towards a 
main effect of time (F15,705 = 17.69, P < 0.05). 
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Figure 3.15 shows the effect of three doses of carbamathione (200 mg/kg, 50 
mg/kg, and 20 mg/kg i.v.) on basal Glu levels in the nucleus accumbens. 
Extracellular basal Glu concentrations were significantly increased (10%-51 %, P 
< 0.05) in the first 3-6 min after carbamathione administration and continued to 
remain elevated over the next 27-39 min with the peak concentrations (29%-101 
%, P < 0.05) occurring 6-9 min after dosing. There was later a significant 
decrease (26%-84%, P < 0.05) in Glu concentrations for the next 66 min. Two-
way ANOVA for repeated measures over time for the data shown in figure 3.15 
revealed a statistically significant main effect of time (F15,705 = 15.20, P < 0.05) 
and a significant interaction between treatment and time (F45,705 = 5.41, P < 0.05), 
but no significant main effect of treatment (F3,47 = 0.48, P < 0.05). 
 
Figure 3.16 shows the effect of three doses of carbamathione (200 mg/kg, 50 
mg/kg, and 20 mg/kg i.v.) on basal DA levels in the nucleus accumbens. 
Carbamathione produced a significant increase (54%-260%, P < 0.05) in 
extracellular basal DA concentrations 3-6 min after dosing and remained elevated 
for the next 75-100 min. The peak increase (95%-616%, P < 0.05) in basal DA 
levels occurred 15-21 min after dosing.  
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Two-way ANOVA for repeated measures over time for the data shown in figure 
3.16 revealed a significant main effect of treatment (F3,47 = 28.59, P < 0.05), a 
significant interaction between treatment and time interaction (F45,705 = 6.49, P < 
0.05), and a trend towards a main effect of time (F15,705 = 13.61, P < 0.05). 
 
Figure 3.17 shows the effect of three doses of carbamathione (200 mg/kg, 50 
mg/kg, and 20 mg/kg i.v.) on basal GABA levels in the prefrontal cortex. 
Carbamathione produced a significant decrease (15%-48%, P < 0.05) in 
extracellular basal GABA concentrations 3-6 min after dosing and remained 
decreased for the next 90-96 min. The lowest concentrations (29%-81%, P < 
0.05) were obtained 53-75 min after dosing. Two-way ANOVA for repeated 
measures over time for the data shown in figure 3.17 revealed a significant main 
effect of treatment (F3,47 = 23.03, P < 0.05), a significant interaction between 
treatment and time interaction (F45,705 = 9.52, P < 0.05), and a trend towards a 
main effect of time (F15,705 = 19.83, P < 0.05). 
 
Figure 3.18 shows the effect of three doses of carbamathione (200 mg/kg, 50 
mg/kg, and 20 mg/kg i.v.) on basal Glu levels in the prefrontal cortex. 
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Extracellular basal Glu concentrations were significantly increased (11%-100 %, 
P < 0.05) in the first 3-6 min after carbamathione administration and continued to 
remain elevated over the next 12-18 min with the peak concentrations (35%-140 
%, P < 0.05) occurring 9-12 min after dosing. There was later a significant 
decrease (29%-79%, P < 0.05) in Glu concentrations for the next 78-90 min. 
Two-way ANOVA for repeated measures over time for the data shown in figure 
3.18  revealed a statistically significant main effect of time (F15,705 = 24.2, P < 
0.05) and a significant interaction between treatment and time (F45,705 = 3.84, P < 
0.05), but no significant main effect of treatment (F3,47 = 0.67, P < 0.05). 
 
Figure 3.19 shows the effect of three doses of carbamathione (200 mg/kg, 50 
mg/kg, and 20 mg/kg i.v.) on basal DA levels in the prefrontal cortex. 
Carbamathione produced a significant increase (11-87%, P < 0.05) in 
extracellular basal DA concentrations 3-6 min after dosing and remained elevated 
for the next 90-114 min. The peak increase (66-395%, P < 0.05) in basal DA 
levels occurred 48-72 min after dosing. Two-way ANOVA for repeated measures 
over time for the data shown in figure 3.19 revealed a significant main effect of 
treatment (F3,47 = 42.03, P < 0.05), a significant interaction between treatment and 
time interaction (F45,705 = 3.23, P < 0.05), and a trend towards a main effect of 
time (F15,705 = 8.46, P < 0.05). 
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Figure 3.20 shows concentration in brain microdialysis samples and plasma 
microdialysis samples versus time profile for carbamathione after the i.v. 
administration of carbamathione (200 mg/kg, 50 mg/kg, and 20 mg/kg). 
Carbamathione concentrations in the plasma and the brain increased to a peak 
after 3 and 6 min, respectively and then proceeded to fall exponentially. The 
pharmacokinetic parameters of carbamathione in brain are given in table 3.21. It 
is important to note that the values for the half-life of carbamathione in the brain 
and plasma obtained by 3 min sampling are very close to those obtained by 5 min 
sampling (see table 3.13). The values obtained for the elimination constants by 3 
min sampling were also very close to those obtained by 5 min sampling. These 
results suggest that 5 min sampling was sufficient to obtain the relevant PK and 
PD data for carbamathione. 
 
3.4 Discussion 
The results from this study show that carbamathione crossed the blood-brain 
barrier (BBB) and administration of carbamathione was correlated with a dose-
dependent change in GABA, Glu, and DA. This finding has implications for 
carbamathione as a possible pharmacological agent in alcohol and cocaine 
addiction. 
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Figure 3.20 Carbamathione concentration versus time profile after three doses 
carbamathione and 3 min sampling interval. 
Concentration of carbamathione in rat brain following carbamathione administration (200 mg/kg, 
50 mg/kg, 20 mg/kg i.v., n = 5). Microdialysis samples were collected every 3 min. Data shown as 
concentration (mean ± SEM).  
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Table 3.21 Pharmacokinetic paramaters of carbamathione with 3 min sampling 
interval. 
Pharmacokinetic parameters of carbamathione in rat brain following carbamathione administration 
(200 mg/kg, 50 mg/kg, and 20 mg/kg i.v., n = 5) and 3 min sample collection. Data expressed as 
mean ± SEM. 
 
Dose Cmax tmax t1/2 Kelim AUC 
200 mg/kg PFC  26.2 ± 6.5 4.5 ± 1.5 4.15 ± 0.37  0.17 ± 0.02 273 ± 66 
200 mg/kg NAc  29.4 ± 7.3 4.5 ± 1.5 4.10 ± 0.48 0.16 ± 0.02 270 ± 67 
200 mg/kg Plasma  182 ± 47 1.5 ± 1.5 4.67 ± 0.41 0.15 ± 0.03 1854 ± 458 
50 mg/kg PFC  9.24 ± 2.64 4.5 ± 1.5 4.14 ± 0.58 0.17 ± 0.03 71.1 ± 21.3 
50 mg/kg NAc  10.1 ± 3.0 4.5 ± 1.5 4.05 ± 0.57  0.17 ± 0.02 84.1 ± 25.2 
50 mg/kg Plasma  45.9 ± 9.4 1.5 ± 1.5 4.37 ± 0.44 0.16 ± 0.03 447 ± 124 
20 mg/kg PFC  3.25 ± 0.43 4.5 ± 1.5 4.17 ± 0.67 0.17 ± 0.03 23.7 ± 6.3 
20 mg/kg NAc  3.72 ± 0.54 4.5 ± 1.5 4.09 ± 0.71 0.17 ± 0.03 29.1 ± 8.1 
20 mg/kg Plasma  25.2 ± 8.3  1.5 ± 1.5 4.34 ± 0.55 0.16 ± 0.04 183 ± 70 
  
PFC= Prefrontal Cortex 
 NAc=Nucleus Accumbens 
Cmax = maximum concentration (µmol/L) 
tmax = time to maximum concentration (min) 
t1/2 = elimination half-life (min) 
Kelim = elimination constant (1/min) 
AUC = area under the dialysate concentration versus time profile (µmol/L min) 
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Alcohol exerts its reinforcing properties through a set of effects on multiple 
neurotransmitter systems that includes agonism or potentiating GABAA, and 
antagonism at the Glu receptors. Alcohol reduces the pace of brain activity in part 
by decreasing the excitatory actions of Glu at the N-methyl-D-aspartic acid 
(NMDA) receptor. Alcohol also causes the release of DA (i.e., stimulant-like 
properties), and may exert some of its acute positively reinforcing properties by 
its effects on dopaminergic systems.18-21 The reinforcing properties and abuse 
liability of cocaine is primarily mediated by its binding action at the DA reuptake 
transporter, which leads to an increase in DA. Both cocaine and alcohol also 
cause an increase in DA transmission by an indirect pathway in which 
GABAergic interneurons that normally inhibit DA neurons are inhibited. In one 
study, the administration of vigabatrin, a drug that enhances brain GABA levels 
abolished a cocaine cue-induced increase in brain DA levels.22 The dopaminergic 
pathways in the nucleus accumbens and prefrontal cortex are the main sites in the 
brain that mediate alcohol and cocaine reinforcement. Dopaminergic activity in 
the nucleus accumbens is regulated by glutamatergic and GABAergic inputs from 
the prefrontal cortex.19-21 
 
Administration of carbamathione was correlated with an initial increase in 
extracellular Glu concentration and a subsequent decrease after 30 min. This 
initial increase was statistically greater in the nucleus accumbens than in the 
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prefrontal cortex. This is interesting because this increase and decrease can be 
correlated with the PK of carbamathione in the brain (figure 3.20). This suggests 
that the initial increase may be due to carbamathione, which is a partial NMDA 
antagonist. The subsequent decrease may be due to a metabolite that is formed 
after carbamathione. The fact that carbamathione may act as a partial NMDA 
antagonist with effects that do not last very long may prove to be an advantage in 
the treatment of cocaine and alcohol addiction. Glu receptor antagonists have 
been used in the treatment of both alcohol and cocaine addiction.18,23-25 
Acamprosate, a drug approved by the FDA for alcohol dependency, has been 
proposed to act on the glutamatergic system. In particular, it has been 
demonstrated that acamprosate acts through the attenuation of a 
‘hyperglutamatergic state’ that underlies acute and protracted alcohol withdrawal, 
and is associated with alcohol craving and relapse. This mode of action of 
acamprosate suggests that the blockade of Glu receptors could reduce relapse and 
craving. In fact, memantine and neramexane, both NMDA blockers, can attenuate 
cue-induced craving in a dose-dependent fashion in alcohol-dependent patients by 
producing alcohol-like effects. This provides a new concept in replacement 
therapy for alcoholism.25 Another study showed that delivering cues associated 
with cocaine during self-administration training reliably reinstated active lever 
responding after extinction and systemic administration of Glu antagonists 
significantly attenuated cue-induced reinstatement.26 Glutamatergic signaling 
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between the prefrontal cortex and nucleus accumbens has been demonstrated to 
be essential for cue-induced drug seeking behavior. Pharmacological agents 
capable of reducing glutamatergic signaling within these regions may potentially 
provide a mechanism through which to promote abstinence.27,28  
 
Administration of carbamathione was correlated with an increase in DA levels in 
the brain. The increase of DA in the nucleus accumbens was more pronounced 
than the increase in the prefrontal cortex. This difference was statistically 
significant. This is expected since carbamathione also appeared to decrease 
GABA in the prefrontal cortex which usually inhibits DA in the nucleus 
accumbens. The DA efflux evoked by carbamathione appeared to be reversible 
over time which seems to exclude short-term cytotoxic implications. The role of 
DA in mediating the rewarding effects of drugs of abuse has been well 
established. DA has been demonstrated to play a significant role in the 
development of craving and withdrawal when alcohol and cocaine are abused. 
Replacement treatments for cocaine dependence involve replacing cocaine’s 
effects at the DA reuptake transporter and replacing postsynaptic DA with DA 
agonists. 18,19,29-31 Among the DA-enhancing agents, amantadine has shown some 
promise in treating patients with cocaine dependence, but this has not been a 
reliable finding. Another replacement approach involves substituting 
amphetamine for cocaine as an agonist since it has been shown to reduce cocaine 
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use in cocaine dependent patients. This would be similar to replacing heroin with 
methadone.18 Another study demonstrated that the acute administration of a 
dopamine antagonist significantly decreased alcohol intake and cue/alcohol-
triggered reinstatement of alcohol-seeking behavior in a model of oral alcohol 
self-administration in mice.32 Carbamathione is a promising pharmacological 
agent since the drugs that enhance dopaminergic function have been also shown 
to reduce the effects of withdrawal from alcohol and cocaine.7,18,33,34 
 
Administration of carbamathione was correlated with a dose-dependent decrease 
in extracellular GABA levels in the nucleus accumbens and the prefrontal cortex. 
The decrease of GABA in the prefrontal cortex was greater than the decrease in 
the nucleus accumbens at 57-72 min after carbamathione administration. This 
difference was statistically significant. As discussed previously, chronic alcohol 
and cocaine use have demonstrated effects on GABAergic transmission in the 
nucleus accumbens, disinhibiting DA neurons in this area as well as GABAergic 
receptor expression and binding characteristics.18,35 GABA agonists such as 
baclofen have been shown to reduce the reinforcing effects of several different 
classes of abused drugs in animal models under a variety of conditions. In 
addition clinical trials have also shown baclofen to be promising in treating 
cocaine addiction and alcoholism.30 Other approaches to altering GABA 
neurotransmission include the use of anticonvulsants. The exact pharmacology of 
 157 
these drugs is not fully understood but most also affect the glutamatergic system. 
Anticonvulsants, such as valproate, tiagabine and topiramate, have shown promise 
in treating cocaine addiction and alcoholism. Since carbamathione appeared to 
decrease GABA with a concurrent increase in DA, an effect seen with both 
alcohol and cocaine, carbamathione may lead to the decrease in craving for 
alcohol or cocaine. Disulfiram was observed to have an anti-craving property in 
clinical trials for the treatment of alcohol and cocaine addiction.36,37 The effect of 
carbamathione on GABA levels further supports a possible role for carbamathione 
in replacement therapy for alcohol and cocaine addiction.  
 
Microdialysis provided important information pertaining to the extracellular 
levels of neurotransmitters in the brain as well as the PK of carbamathione. 
However, one of the drawbacks of the microdialysis technique is that it does not 
provide information about the mechanism of action of carbamathione. Previous 
studies with disulfiram may provide some mechanistic information on the data 
obtained in this investigation. Vaccari et al., 1996 demonstrated that disulfiram 
administration led to DA release from striatal vesicles and inhibited the vesicular 
uptake of [3H]DA.38 Studies from the same laboratory also demonstrated that 
disulfiram evoked a vesicular efflux of Glu and an in vivo striatal release of Glu.39 
These studies may explain some of the changes observed in Glu and DA levels in 
the brain after carbamathione administration in this study since carbamathione is a 
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metabolite of disulfiram. Nagendra et al., 1997 showed that carbamathione was 
formed when S- methyl N, N-diethylthiocarbamate sulfone (DETC-MeSO2), a 
metabolite of disulfiram, carbamoylated glutathione. Carbamathione was 
suggested to cross the BBB and carbamoylate brain Glu receptor in vivo.40 This 
suggests that carbamathione or a metabolite after carbamathione may be 
responsible for the changes observed in brain neurotransmitters after disulfiram or 
carbamathione administration. 
 
It is interesting to note that administration of carbamathione was correlated with 
an effect on multiple neurotransmitter systems. Most of the pharmacotherapy for 
alcoholism and cocaine abuse usually target a single neurotransmitter system and 
multi-drug therapy appeared to be more efficacious that administration of a single 
drug.18,19,30 The effect of carbamathione on multiple neurotransmitters may 
indicate the presence of one or more other metabolites that are formed after 
carbamathione. 
 
3.5 Conclusions 
The work in this chapter showed the application of a MEKC-LIF method for the 
simultaneous detection of GABA, Glu, DA, and carbamathione in rat brain 
dialysate and an LC-MS/MS method for the detection of carbamathione in plasma 
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dialysate. The analytical methods were validated and exhibited good linearity, 
accuracy and reproducibility with nanomolar and sub-nanomolar detection limits. 
The administration of three doses of carbamathione was correlated with changes 
in the brain neurotransmitter systems in awake rats. Administration of 
carbamathione was correlated with dose-dependent changes in GABA, Glu, and 
DA in both the prefrontal cortex and nucleus accumbens. Carbamathione was also 
determined in plasma dialysate and allowed the determination of PK parameters. 
Although carbamathione administration was correlated with changes in brain 
neurotransmitters, the mechanism by which this occurred remains unknown. 
Future studies will focus on elucidating this mechanism by studying selectively 
inhibiting disulfiram metabolism and investigating whether changes in brain 
neurotransmitters were observed. 
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4 INHIBITION OF DISULFIRAM METABOLISM AND ITS EFFECT 
ON BRAIN NEUROTRANSMITTERS 
4.1 Introduction 
In Chapter 3, the pharmacokinetics (PK) and pharmacodynamics (PD) of 
carbamathione were determined in a dose-dependent manner. The next step in the 
development of carbamathione as a potential pharmacological agent for alcohol 
and/or cocaine addiction was to demonstrate in vivo the relationship between 
carbamathione and disulfiram. This is an important step since disulfiram is 
approved by the U.S. Food and Drug Administration and has been used as a 
deterrent in alcoholism for over 60 years. There are several clinical studies with 
disulfiram, but none at the present time with carbamathione. It is thus important to 
establish the relationship between the changes in brain neurotransmitters after 
disulfiram administration and carbamathione. This chapter describes a laboratory-
built micellar electrokinetic chromatography coupled with laser-induced 
fluorescence (MEKC-LIF) system used to determine the relationship between 
carbamathione and disulfiram administration, and the brain neurotransmitters. 
 
4.1.1 Background and Significance 
Although substantial progress has been made in understanding the molecular basis 
of alcohol and cocaine addiction, complete knowledge of the neural substrates 
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associated with drug abuse is still not definitive. Therefore there is no medication 
specifically approved to treat cocaine addiction.1 The possibility of developing a 
drug that treats the craving aspect of addiction regardless of the substance being 
abused is an exciting one that warrants further study. Recent use of disulfiram in 
alcohol and cocaine addiction suggests that it can curb some of the craving effects 
of these addictions.2-5 However, carbamathione offers many advantages over 
disulfiram as an anti-addiction drug. First, carbamathione does not inhibit 
aldehyde dehydrogenase (ALDH2), so the unpleasant effects caused by disulfiram 
are eliminated. Second, disulfiram requires bioactivation by several cytochrome 
P450 enzymes, and there are several drugs and food items that can inhibit these 
enzymes. Third, several disulfiram metabolites are known to be toxic and may 
contribute to some of the reported adverse effects associated with disulfiram. 
Carbamathione does not form any of these toxic intermediates.6  
 
 
4.1.2 Specific Aims of Research 
The MEKC-LIF method used in Chapter 3 was modified and optimized for a 
laboratory-built system. In the method described in Chapter 3, a temporal 
resolution of 5 min was determined to be sufficient to obtain relevant PK and PD 
data. The goal of this research was to apply an MEKC-LIF method to determine 
the changes in rat brain neurotransmitters as related to the administration of 
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disulfiram and an inhibitor of disulfiram metabolism. Disulfiram metabolism can 
be inhibited by a non-specific cytochrome P450 enzyme inhibitor such as N-
benzylimidazole (NBI). The administration of NBI with disulfiram should thus 
prevent disulfiram from being metabolized to carbamathione and block any 
neurochemical effect. Our hypothesis was that carbamathione is the proposed 
active metabolite of disulfiram and the administration of NBI with carbamathione 
should not have an effect on carbamathione-induced changes in brain 
neurotransmitters. Carbamathione does not require cytochrome P450 enzymes for 
activation. Thus even if a metabolite of carbamathione is responsible for the 
changes observed in brain neurotransmitters, NBI administration would not 
interfere with the formation of the metabolite. It would also indicate that if a 
metabolite is formed in the brain, it is not a cytochrome P450 metabolite. 
 
4.2 Experimental 
4.2.1 Chemicals and Reagents 
In addition to the chemicals used in Chapter 2 and 3 (2.2.1 & 3.2.1 Chemicals and 
Reagents), disulfiram, NBI, and fluorescein were purchased from Sigma (St. 
Louis, MO, USA).  Artificial cerebrospinal fluid (aCSF) was prepared as 
described in Chapter 2 (2.2.1 Chemicals and Reagents). Ringer’s solution was 
prepared as described in Chapter 3 (3.2.1 Chemicals and Reagents). Standard 
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solutions of amino acids and carbamathione were prepared as previously 
described in Chapter 3 (3.2.1 Chemicals and Reagents). The background 
electrolyte (BGE) consisted of 22.5 mmol/L lithium tetraborate (LTB) (pH 9.2), 
25 mmol/L lithium dodecylsulfate (LDS) and 10% methanol (MeOH). The borate 
buffer for derivatization was prepared as described in Chapter 2 (2.2.1 Chemicals 
and Reagents). The derivatization reaction was carried out as described in Chapter 
2 (2.2.2 Derivatization).  
 
4.2.2 Laboratory–Built MEKC-LIF Instrumentation 
The laboratory-built electrophoretic system was set up as shown in figure 4.1. A 
high voltage direct-current power supply (CZE 1000R, Spellman High Voltage 
Electronics, Hauppauge, NY) was used and was capable of delivering 0-30 kV. 
The separations were performed on a 50 µm id fused-silica capillary (Polymicro 
Technology, Phoenix, AZ, USA) suspended between two electrodes that were 
immersed in reservoirs filled with the BGE. The length of the fused-silica 
capillary was 65 cm (50 cm effective). The capillary and the inlet electrode 
reservoir were enclosed in a Plexiglass box (made of polymethyl methacrylate) 
with an interlock safety system. The outlet electrode reservoir was part of the 
fluorescence detector (ZETALIF, Picometrics, Toulouse, France).  
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Figure 4.1 Schematic diagram of laboratory-built MEKC-LIF system.7 
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Excitation was performed by a diode pumped solid-state laser (CrystaLaser, Reno, 
NV, USA) at an excitation wavelength of 442 nm. An on-column optical cell was 
made by removing the polyimide coating from a short section of the fused-silica 
capillary. The incident laser beam was aligned to its optimum position by 
adjusting the position of collecting optics between the capillary and the detector. 
A 1 µmol/L solution of fluorescein in ultrapure water was used for alignment until 
maximum absorbance was observed.   
 
Hydrodynamic injections were performed by a laboratory-built pressure injection 
system. An argon gas tank (Lindweld, Lincoln, NE, USA) was set up with a 
pressure regulator (Fisher Scientific, Pittsburgh, PA, USA). A union-T was used 
to connect the regulator to a three-way valve that controlled the flow of pressure 
to the sample vial. The three-way valve was connected to a solenoid valve with an 
electronic timer. The capillary and the electrode were inserted through gas-tight 
septa on sample or buffer vials. To make a hydrodynamic injection, the sample 
vial was pressurized (at a pressure set by the pressure regulator) for the 
predetermined amount of time. 
 
Each day, before the analyses were performed, the capillary was sequentially 
flushed at 20 psi with MeOH for 5 min, ultrapure water for 5 min, 1 mol/L 
hydrochloric acid (HCl) for 10 min, ultrapure water for 5 min, 1 mol/L sodium 
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hydroxide (NaOH) for 20 min, ultrapure water for 5 min, and finally with the 
BGE for 10 min. Between analyses, the capillary was flushed at 20 psi with 1 
mol/L NaOH for 2.5 min, with ultrapure water for 1.5 min and then with the BGE 
for 2.5 min. All the solutions injected onto the capillary were sterilized using a 
disposable 0.22 m polyethersulfone (PES) membrane syringe filter (Millipore, 
Co. Cork, Ireland). Each day, an Ohm’s law test was performed to establish that 
there was a linear relationship between the applied electric field and the current 
within the capillary. Electropherograms were acquired on Chrom&Spec version 
1.5 software (Ampersand International,Inc., Beachwood, OH, USA). 
 
4.2.3 Method Development 
As described in Chapter 3, the BGE consisted of 22.5 mmol/L LTB (pH 9.2) and 
20 mmol/L LDS and the capillary temperature was reduced to 15° C to optimize 
the separation. However, with the laboratory-built MEKC-LIF system used for 
these studies it is difficult to reproducibly cool the capillary to this temperature. 
Therefore, experiments to optimize the separation buffer were carried out by 
varying the concentration of the surfactant and adding MeOH to increase the 
viscosity of the BGE. 
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Experiments to optimize the separation buffer were carried out using standards of 
gamma-amino butyric acid (GABA), glutamate (Glu), dopamine (DA), and 
carbamathione. Figure 4.2 displays the effect of increasing the surfactant 
concentration. Increasing the concentration of LDS resulted in shorter analysis 
times and improved peak shapes, but it also led to loss of resolution. Figure 4.3 
shows the effect of adding MeOH to the BGE. Addition of increasing amounts of 
MeOH resulted in improved resolution and peak shapes, but also in longer 
analysis times. Figure 4.3 shows that 10% MeOH produced improved resolution 
without greatly lengthening the analysis time. Once this observation was made, it 
was important to study the effect of varying the concentration of the surfactant in 
the presence of 10% MeOH. Figure 4.4 displays the results of this experiment. 
The run buffer ultimately chosen for the separation consisted of 22.5 mmol/L 
LTB (pH 9.2), 25 mmol/L LDS and 10% MeOH because it represented a good 
compromise between run time and peak resolution with good peak shape. The 
resolution data with this buffer indicated good separation between standards (R > 
1.5) for all pairs tested.  
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Figure 4.2 Effect of varying the concentration of the surfactant on separation. 
Effect of varying LDS concentration on separation of NDA-derivatized carbamathione (1), GABA 
(2), IS (3), Glu (4), and DA (5). IS was 2-ABA. Electropherograms were obtained using 22.5 
mmol/L LTB and varying concentrations of LDS under a 15 kV voltage. NDA-derivatized 
compounds were detected using LIF detection (ex. 442 nm).  
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As described in Chapter 3 (3.2.2 MEKC-LIF Instrumentation), samples were 
introduced onto the capillary by hydrodynamic injections for 15 s at 0.7 psi. 
However, the pressure regulator used in the laboratory-built pressure injection 
system could not accurately reproduce pressures below 5 psi. The hydrodynamic 
injection described in Chapter 2 represented an injection volume of 17.09 µL and 
a sample plug that was 1.34% of capillary length. A hydrodynamic injection at 5 
psi with varying times of injection was investigated. A 2 s injection at 5 psi was 
chosen as it was a good compromise between separation and sensitivity. This 
hydrodynamic injection represented an injection volume of 16.27 µL and a 
sample plug that was 1.27% of capillary length.  
 
In Chapter 3 (3.2.2 MEKC-LIF Instrumentation) a two-step separation voltage (10 
kV for 10 min and 20 kV for 8 min) was described. Since the change in voltage at 
10 min would have to be performed manually on a laboratory-built MEKC-LIF 
system, the separation voltage was re-evaluated. Voltages between 10-30 kV were 
tested and the best separation was obtained at 15 kV.  
 
Peak identification in microdialysis samples were carried out by comparing 
migration times to those present in standards. During this study it was observed 
that the IS (2-ABA) co-migrated with an endogenous peak. A new IS (AAP) was 
used since it did not co-migrate with any endogenous peak or interfere with any of 
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the standards. Figure 4.5 displays electropherograms obtained for standards, 
microdialysis samples and microdialysis sample spiked with standards. The 
observed height of the peaks of interest increased when exogenous Glu, GABA, 
DA, and carbamathione were added to the microdialysis samples. No additional 
peaks appeared when Glu, GABA, DA, and carbamathione were added. 
Background peaks associated with NDA derivatization did not interfere with any 
of the analytes of interest.  
 
In summary, separations were carried out using BGE consisting of 22.5 mmol/L 
LTB and 25 mmol/L LDS (10% MeOH) at a running voltage of 15 kV in 65 x 50 
µm id fused-silica capillary (50 cm effective). Separations were performed at 
room temperature (25° C). Figure 4.5 shows a typical electropherogram of 
derivatized microdialysis sample from the rat brain.  
 
4.2.4 Method Validation Experiments 
Calibration standards for method validation contained GABA prepared in 
concentration range of 10-9- 10-6 mol/L, Glu prepared in a range of 10-9- 10-6 
mol/L, DA in a range of 10-10- 10-7 mol/L and carbamathione prepared in a range 
of 10-8- 10-5 mol/L. 
 
Figure 4.
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Calibration plots were plotted as the ratio of the area of compound of interest to 
area of the internal standard versus concentration (number of concentrations of 
each analyte, n = 5). The limits of detection and quantification were calculated as 
the analyte concentration that resulted in peaks with signal-to-noise ratio (S/N) of 
3 and 10 respectively. Intra-day and inter-day reproducibility were determined 
using standards of Glu, GABA, DA, and carbamathione prepared in aCSF and 
microdialysis samples. The accuracy of the method was calculated from the 
analysis of standards in aCSF, microdialysis samples and microdialysis samples 
spiked with known concentrations of standards (in triplicate). 
 
4.2.5 Microdialysis 
4.2.5.1 Brain and Vascular Probes 
Brain microdialysis probes (CMA 12 Elite) with 2 mm membranes were 
purchased from CMA Microdialysis (North Chelmsford, MA, USA). The 
fabrication of vascular probes in-house and the relative recovery of carbamathione 
through the microdialysis probes were as described in Chapter 3 (3.2.8.1 Brain 
and Vascular Probes).  
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4.2.5.2 Animals and Surgery 
All awake experiments were carried out in accordance with Institutional Animal 
Care and Use Committee (IACUC) animal protocols as described in Chapter 2 
(2.2.6.2 Animals and Surgery). Sterile surgeries were conducted as described in 
Chapter 3 (3.2.8.2 Animals and Surgery). The initial anesthesia and preparation of 
the incision sites are described in detail in Chapter 2 (2.2.6.2 Animals and 
Surgery).  
 
An intraperitoneal (i.p.) cannula (PE-50) was implanted into the abdomen for 
dosing purposes. The cannula was sterilized by ethylene oxide. A small area at the 
back of the neck and the lower abdomen was shaved and disinfected. The animal 
was then transferred to a sterile field and draped. A small incision was made in 
the skin and then through the muscle at the mid-line of the abdomen. Five to ten 
cm of the cannula was inserted into the abdominal cavity so that the end of the 
cannula lies between the small intestine and the ventral cavity wall. The cannula 
was held in place by suturing it to the edge of the opening in the muscle wall. The 
muscle incision was sutured and the free end of the cannula was externalized 
through a sterile incision at the back of the neck. The abdominal skin incision was 
sutured and the incision at the back of the neck closed with suture or tissue glue. 
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Microdialysis probes were implanted into brain nucleus accumbens as described 
in Chapter 2 (2.2.6.2 Animals and Surgery) and into the jugular vein as described 
in Chapter 3 (3.2.8.2 Animals and Surgery). After the surgical procedures, the rats 
were administered 0.5 to 3 mL/kg of saline subcutaneously (s.c.) and placed in a 
rat turn with a heating pad to facilitate recovery from anesthesia. 
 
4.2.5.3 Microdialysis Sample Collection 
Microdialysis samples were collected as described in Chapter 3 (3.2.8.3 
Microdialysis Sample Collection). After implantation, the brain probes and the 
vascular probes were perfused with aCSF and Ringer’s solution, respectively, at 2 
µL/min. The dead volume between the dialysis site and the fraction collector was 
also determined in order to accurately monitor the neurochemical changes as 
described in Chapter 3 (3.2.8.3 Microdialysis Sample Collection). 
 
4.2.5.4 In Vivo Experiments 
The collection of 5 min samples was initiated after a 24 h waiting period for 
awake experiments. For dosing purposes, the carbamathione dose (200 mg/kg) 
was prepared by adding a few drops of 1 mol/L sodium bicarbonate solution and 
bringing the volume up to 1 mL with saline solution. The disulfiram dose (200 
mg/kg) was prepared as suspension in saline solution. The NBI dose (20 mg/kg) 
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was prepared by adding saline, a few drops of 0.1 mol/L HCl solution and 
sonicating the solution. After the i.p. administration of carbamathione, disulfiram, 
or NBI through the i.p. cannula, microdialysis samples were collected for 3 h. At 
the end of the experiments, the rats were sacrificed by placement in an isofluorane 
chamber for approximately 30 min. Rat brains were harvested in order to perform 
a histological confirmation of brain probe position as described in Chapter 2 
(2.3.3 Histological Confirmation of Brain Probe Position).  
 
4.3 Results and Discussion 
4.3.1 Method Validation Results 
Validation was carried out in accordance with instructions for good laboratory 
practice.8,9 Validation parameters were determined for GABA, Glu, DA, and 
carbamathione in standards as well as brain microdialysis samples. The final 
results are shown in table 4.6. The regression coefficient of the calibration 
obtained with standard solutions and microdialysis samples showed good linearity 
and led to the routine use of only three points of the calibration curve. A complete 
calibration curve was obtained every time the capillary was changed. Limits of 
detection and quantification were lower than concentrations measured in 
microdialysis samples from the brain.  
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Table 4.6 Quantitative parameters for the analysis GABA, Glu, DA, and 
carbamathione in aCSF and microdialysis samples. 
 
 aCSF GABA Glu DA Carb 
Calibration Range (mol/L) 10-9-10-6 10-9-10-6 10-10-10-7 10-8-10-5 
Regression Coefficient of Calibration (r²) 0.9999 0.9988 0.9902 0.9992 
Intra-day repeatability (%RSD)a 9.6 3.9 10.4 7.7 
Inter-day repeatability (%RSD)b 5.8 8.1 9.5 9.1 
Accuracy (%)c 4.2-2.1 6.3-3.4 8.0-5.9 4.1-2.6 
Limits of Detection (mol/L) 6.0 x 10-9 1.0 x 10-8 5.0 x 10-9 1.0 x 10-8 
Limits of Quantification (mol/L) 3.0 x 10-8 3.0 x 10-7 2.5 x 10-8 5.0 x 10-7 
 Microdialysis Samples GABA Glu DA Carb 
Calibration Range (mol/L)d 10-9-10-6 10-9-10-6 10-10-10-7 10-8-10-5 
Regression Coefficient of Calibration (r²) 0.9983 0.9909 0.9800 0.9976 
Intra-day repeatability (%RSD)a 10.2 9.8 12.3 9.2 
Inter-day repeatability (%RSD)b 8.4 8.1 9.9 9.7 
Accuracy (%)c,d 10.3-6.9 9.5-6.4 10.0-6.1 8.5-5.1 
 
a. Five replicates 
b. Five days, three replicates each 
c. Three replicates, tested concentration of 10-7 mol/L for GABA, Glu, DA and 
carbamathione 
d. Spiked microdialysis samples  
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4.3.2 In Vivo Studies 
In this study, all the agents were administered i.p. This was done in order to be 
consistent since disulfiram is extremely insoluble in water and saline solution and 
has to be administered as a suspension. Linear regression analysis was performed 
to test the existence of a statistically significant linearity for the calibration 
curves. Changes in concentration of Glu, GABA, and DA were expressed as 
percent of the basal concentration, measured before drug or vehicle 
administration. Data are given as mean ± standard error of mean (SEM). 
Comparison between treated and control rats were achieved on percentage 
transformed data using analysis of variance (ANOVA) and post-hoc comparison 
by Tukey-Kramer test. The level of significance was set at P < 0.05 for all 
comparisons. 
 
4.3.2.1 Pharmacokinetic Studies 
4.3.2.1.1 Administration of Disulfiram (200 mg/kg i.p.) 
Figure 4.7 shows concentration in brain nucleus accumbens microdialysis samples 
and plasma microdialysis samples versus time profile for carbamathione after the 
i.p. administration of disulfiram (200 mg/kg, n = 3). Carbamathione 
concentrations in the plasma and the brain increased to a peak at 90 and 95 min 
after administration, respectively and then proceeded to fall.  
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Figure 4.7 Carbamathione concentration versus time profile after a 200 mg/kg dose of 
disulfiram. 
Concentration of carbamathione in rat brain nucleus accumbens following disulfiram 
administration (200 mg/kg i.p., n = 3). Microdialysis samples were collected every 5 min. Data 
shown as concentration (mean ± SEM).  
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As expected, there was a slow increase in carbamathione concentrations since 
disulfiram was administered i.p. In addition, the clearance of carbamathione could 
not be monitored completely due to this long distribution phase. The Cmax for 
carbamathione concentrations after disulfiram administration in the plasma and 
the brain nucleus accumbens were 61.1 ± 10.2 nmol/L and 10.0 ± 1.9 nmol/L 
respectively. In comparison, the Cmax for carbamathione concentrations after the 
intravenous (i.v.) administration of the lowest dose of carbamathione (20 mg/kg 
i.v.) in the plasma and the brain nucleus accumbens were 25.2 ± 8.3 µmol/L and 
3.72 ± 0.54 µmol/L respectively (see table 3.21). Interestingly, the ratio of the 
Cmax for carbamathione in the brain to the Cmax for carbamathione in the plasma 
remained very similar regardless of dose or route of administration.  The area 
under the dialysate concentration versus time profile (AUC) for carbamathione in 
the brain nucleus accumbens and plasma after the administration of disulfiram 
(200 mg/kg i.p.) were 729 ± 174 nmol/L min and 4.05 ± 1.30 µmol/L min. A 200 
mg/kg dose of carbamathione and a 200 mg/kg dose of disulfiram are 
approximately equimolar. Therefore, a percent conversion of disulfiram to 
carbamathione can be estimated for the administration of disulfiram based on 
carbamathione concentrations in the plasma and brain. It was determined to be 
less than 1% of disulfiram was ultimately converted to carbamathione.  
 
 189 
4.3.2.1.2 Administration of NBI (20 mg/kg i.p.) and Disulfiram (200 mg/kg 
i.p.) 
NBI (20 mg/kg i.p.) was administered 30 min prior to administration of saline 
vehicle or disulfiram (200 mg/kg i.p.) and 30 min after administration in order to 
ensure maximum inhibition of cytochrome P450. This dosing scheme has been 
used in previous studies into the metabolites of disulfiram.10 Carbamathione 
concentrations in the microdialysis samples from the brain nucleus accumbens 
were determined to be below the limits of detection for the MEKC-LIF system. 
Liquid chromatography- tandem mass spectrometric (LC-MS/MS) analysis of 
microdialysis samples from the plasma indicated that the concentrations of 
carbamathione detected were less than 1 nmol/L in comparison with a Cmax of 
61.1 ± 10.2 nmol/L after disulfiram administration alone. These results suggest 
that NBI was successful in inhibiting the formation of carbamathione from 
disulfiram by inhibiting cytochrome P450.  Cytochrome P450 enzymes appear to 
be essential for disulfiram to be ultimately converted to carbamathione. 
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4.3.2.1.3 Administration of NBI (20 mg/kg i.p.) and Carbamathione (200 
mg/kg i.p.) 
The effect of dosing NBI (20 mg/kg) in combination with carbamathione (200 
mg/kg) was also evaluated. Figure 4.8 shows concentration in brain nucleus 
accumbens microdialysis samples and plasma microdialysis samples versus time 
profile for carbamathione after the i.p. administration of carbamathione (200 
mg/kg, n = 3) following NBI administration. Carbamathione concentrations in the 
plasma and the brain nucleus accumbens increased to a peak at 15 and 25 min 
after administration, respectively and then proceeded to fall exponentially. The 
PK parameters of carbamathione in brain nucleus accumbens are given in table 
4.9. It must be pointed out that the PK of the clearance of carbamathione from the 
plasma and brain nucleus accumbens was similar to the values previously 
obtained after the i.v. administration of carbamathione alone (see tables 3.13 and 
3.21). For instance, the AUC for carbamathione concentrations in the brain 
nucleus accumbens and plasma after carbamathione administration (200 mg/kg 
i.v.) were 308 ± 81 µmol/L min and 2310 ± 628 µmol/L min, respectively (table 
3.13). In comparison, the AUC for carbamathione concentrations in the brain 
nucleus accumbens and plasma after dosing a combination of NBI (20 mg/kg i.p.) 
and carbamathione (200 mg/kg i.p.) were 244 ± 84 µmol/L min and 1990 ± 501 
µmol/L min, respectively. This indicated that NBI did not interfere with the PK of 
carbamathione.  
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Figure 4.8 Carbamathione concentration versus time profile after a 200 mg/kg dose of 
carbamathione. 
Concentration of carbamathione in rat brain nucleus accumbens following carbamathione 
administration (200 mg/kg i.p., n = 3). Microdialysis samples were collected every 5 min. Data 
shown as concentration (mean ± SEM).  
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Table 4.9 Pharmacokinetic paramaters of carbamathione with 5 min sampling 
interval. 
Pharmacokinetic parameters of carbamathione in rat brain nucleus accumbens following 
carbamathione administration (200 mg/kg i.p., n = 3) and 5 min sample collection. Data expressed 
as mean ± SEM. 
 
200 mg/kg  Cmax  tmax t1/2 Kelim AUC 
Brain 9.21 ± 1.87 22.5± 2.5 4.38 ± 0.52 0.14 ± 0.03 244 ± 84 
Plasma  93.8 ± 16.5 12.5± 2.5 4.94 ± 1.05 0.15 ± 0.03  1990 ± 501 
 
 
Cmax = maximum concentration (µmol/L) 
tmax = time to maximum concentration (min) 
t1/2 = elimination half-life (min) 
Kelim = elimination constant (1/min) 
AUC = area under the dialysate concentration versus time profile (µmol/L min) 
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4.3.2.2 Pharmacodynamic Studies 
4.3.2.2.1 Administration of Disulfiram (200 mg/kg i.p.) 
The effect of disulfiram administration (200 mg/kg i.p.) on basal levels of GABA, 
Glu, and DA in the rat brain nucleus accumbens is shown in figure 4.10. 
Microdialysis samples from the brain nucleus accumbens and plasma were 
analyzed utilizing the laboratory-built MEKC-LIF system described in this 
chapter and the LC-MS/MS described in Chapter 3 (3.2.5 LC-MS/MS 
Instrumentation).   
 
Basal Glu concentrations were significantly increased by 29% (P < 0.05 Tukey-
Kramer test) at the ninth fraction 5 (i.e. + 45 min) after disulfiram administration. 
The increase in Glu concentration from basal levels continued over the next 30 
min after carbamathione administration with a peak increase of 35% (P < 0.05 
Tukey-Kramer test) at the fifteenth fraction (i.e. + 75 min). However, during the 
next 10 min Glu concentration was reduced by 12% (P < 0.05 Tukey-Kramer test) 
and continued to remain reduced over the next 30 min. The lowest concentration 
of Glu was obtained in the twenty-third fraction (i.e. + 115 min) where basal Glu 
concentrations were significantly reduced by 20 % (P < 0.05 Tukey-Kramer test).  
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Basal GABA concentrations were significantly increased by 23% (P < 0.05 
Tukey-Kramer test) in the first fraction following disulfiram administration. 
However, basal GABA levels decreased in the next 10 min and continued to 
remain reduced over the next 2 h following disulfiram administration. The lowest 
concentration of GABA was obtained in the nineteenth fraction (i.e. + 95 min) 
where basal GABA concentrations were significantly reduced by 22 % (P < 0.05 
Tukey-Kramer test).  
 
Basal DA concentrations were significantly increased by 45% (P < 0.05 Tukey-
Kramer test) in the ninth fraction (i.e. + 45 min) following disulfiram 
administration, and continued to remain increased over the next 75 min. The 
highest concentration was obtained in the nineteenth fraction (i.e. + 95 min) 
where basal DA concentrations were significantly increased by 111 % (P < 0.05 
Tukey-Kramer test).  
 
After disulfiram administration, the neurotransmitters concentrations did not 
appear to change to the same extent as the changes in neurotransmitter 
concentration when the lowest dose (20 mg/kg) of carbamathione was 
administered.  This may be because only a small percentage of disulfiram was 
metabolized to carbamathione (<1%).  
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4.3.2.2.2 Administration of NBI (20 mg/kg i.p.) and Disulfiram (200 mg/kg 
i.p.) 
The comparison between the effect of NBI (20 mg/kg i.p.) alone and the effect of 
NBI (20 mg/kg i.p.) in combination with disulfiram administration (200 mg/kg 
i.p.) on basal levels of GABA, Glu, and DA in the rat brain nucleus accumbens is 
shown in figure 4.11. NBI was administered 30 min prior to administration of 
saline vehicle or disulfiram and 30 min after administration in order to ensure 
maximum inhibition of cytochrome P450. This dosing scheme has been used in 
previous studies on the inhibition of disulfiram metabolism.10 Microdialysis 
samples from the brain nucleus accumbens and plasma were analyzed utilizing 
the laboratory-built MEKC-LIF system described in this chapter and the LC-
MS/MS described in Chapter 3 (3.2.5 LC-MS/MS Instrumentation).   
 
As seen in figure 4.11, there was no statistical difference in GABA, Glu, or DA 
levels following administration of NBI and NBI in combination with disulfiram 
(P < 0.05 Tukey-Kramer test). There was a slight increase in DA and Glu upon 
injection of either NBI or DA. However, this increase was not statistically 
significant (P < 0.05 Tukey-Kramer test).  These results also indicate that the 
inhibition of cytochrome P450 blocked the changes observed in brain 
neurotransmitters when disulfiram was administered alone. 
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Figure 4.11 GABA, Glu, and DA in rat brain nucleus accumbens after after a 200 
mg/kg dose of disulfiram and a 20 mg/kg dose of NBI. 
White squares represent experiments with disulfiram and NBI administration (n = 3) and black 
squares represent controls (n = 3).  0 min indicates time point of disulfiram administration (200 
mg/kg i.p.). Arrows indicate time points of NBI administration (20 mg/kg i.p.).  
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This suggests that the changes observed in neurotransmitter levels after disulfiram 
administration may be due to carbamathione or a metabolite formed after 
carbamathione formation. An important experiment that can be used to confirm 
this finding is the administration of carbamathione in combination with NBI.  
 
4.3.2.2.3 Administration of NBI (20 mg/kg i.p.) and Carbamathione (200 
mg/kg i.p.) 
The comparison between the effect of NBI (20 mg/kg i.p.) alone and the effect of 
NBI (20 mg/kg i.p.) in combination with carbamathione administration (200 
mg/kg i.p.) on basal levels of GABA, Glu, and DA in the rat brain nucleus 
accumbens is shown in figure 4.12. NBI was administered 30 min prior to 
administration of saline vehicle or carbamathione and 30 min after administration 
in order to ensure maximum inhibition of cytochrome P450. Microdialysis 
samples from the brain and plasma were analyzed utilizing the laboratory-built 
CE system described in this chapter and the LC-MS/MS described in Chapter 3 
(3.2.5 LC-MS/MS Instrumentation).   
 
There was a significant difference in the neurotransmitter levels observed between 
the administration of NBI alone and NBI in combination with carbamathione.  
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Figure 4.12 GABA, Glu, and DA in rat brain nucleus accumbens after after a 200 
mg/kg dose of carbamathione and a 20 mg/kg dose of NBI. 
White squares represent experiments with carbamathione administration (n = 3) and black squares 
represent controls (n = 3).  0 min indicates time point of carbamathione administration (200 mg/kg 
i.p.). Arrows indicate time points of NBI administration (20 mg/kg i.p.). 
 
 200 
Basal Glu concentrations were significantly increased by 36% (P < 0.05 Tukey-
Kramer test) in the first 5 min fraction after carbamathione administration. The 
increase in Glu concentration from basal levels continued over the next 50 min 
after carbamathione administration with a peak increase of 77% (P < 0.05 Tukey-
Kramer test) at the fifth fraction (i.e. + 25 min). However, during the next 30 min 
Glu concentration was reduced by 50% (P < 0.05 Tukey-Kramer test) and 
continued to remain reduced over the next 65 min. The lowest concentration of 
Glu was obtained in the fifteenth fraction (i.e. + 75 min) where basal Glu 
concentrations were significantly reduced by 60% (P < 0.05 Tukey-Kramer test).  
 
Basal GABA concentrations were significantly decreased by 14% (P < 0.05 
Tukey-Kramer test) in the first fraction following carbamathione administration 
and continued to remain reduced over the next 2 h following carbamathione 
administration. The lowest concentration of GABA was obtained in the fifteenth 
fraction (i.e. + 75 min) where basal GABA concentrations were significantly 
reduced by 53% (P < 0.05 Tukey-Kramer test).  
 
Basal DA concentrations were significantly increased by 21% (P < 0.05 Tukey-
Kramer test) in the first fraction following carbamathione administration, and 
continued to remain increased over the next 2 h. The highest concentration of DA 
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was obtained in the sixth fraction (i.e. + 30 min) where basal DA concentrations 
were significantly increased by 232% (P < 0.05 Tukey-Kramer test). 
 
Since administration of carbamathione in combination with NBI restored the 
changes in neurotransmitter observed with carbamathione and disulfiram alone, 
these changes may be attributed to carbamathione or a metabolite that is formed 
after carbamathione rather than to disulfiram. 
 
4.4 Discussion 
These studies demonstrated that carbamathione was produced from disulfiram 
since it was detected in the brain after disulfiram administration but was not 
detected when an inhibitor of disulfiram metabolism was administered. This 
suggests that disulfiram has to be bioactivated during the phase I metabolism 
before carbamathione is formed from by glutathione conjugation in phase II 
metabolism (see figure 1.4). Phase I metabolism involved cytochrome P450 
enzymes and phase II metabolism involved the carbamoylation of glutathione. 
These studies suggest that the changes observed in GABA, Glu, and DA are due 
to carbamathione and not disulfiram or any of the intermediate metabolites of 
disulfiram. 
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Disulfiram has been observed to be efficacious in clinical trials investigating the 
treatment of cocaine and alcohol addiction.4,5,11,12 The findings in the present 
study suggest that this efficacy may be attributed to carbamathione since it crosses 
the BBB and its administration was correlated with changes in brain 
neurotransmitters. Disulfiram administration also appeared to be correlated with 
changes in brain GABA, Glu, and DA levels, albeit to a much lesser degree than 
carbamathione administration. This may be because disulfiram is slowly absorbed 
and forms several metabolites before ultimately forming carbamathione. Thus the 
percentage of disulfiram that is metabolized to carbamathione is very low. When 
disulfiram metabolism was inhibited, there were no statistically significant 
changes observed in the brain GABA, Glu, and DA levels. However, when 
carbamathione was administered after NBI administration, statistically significant 
changes in the brain GABA, Glu, and DA levels were found, and these changes 
were similar to those observed after carbamathione and disulfiram administration. 
Since NBI did not appear to have an effect on carbamathione administration, 
cytochrome P450 enzymes do not appear to be involved in the possible formation 
of metabolites after carbamathione.  
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4.5 Conclusions 
The work in this chapter showed the development of a laboratory-built MEKC-
LIF method for the simultaneous detection of GABA, Glu, DA, and 
carbamathione in rat brain dialysate. The analytical method was validated and 
exhibited good linearity, accuracy, and reproducibility with nanomolar detection 
limits. This method was applied to the study of the effect of disulfiram on brain 
GABA, Glu and DA levels in the presence of a cytochrome P450 inhibitor. The 
administration of disulfiram (200 mg/kg, i.p.) was correlated with changes in the 
brain GABA, Glu, and DA systems in awake rats. Administration of an inhibitor 
of disulfiram metabolism, NBI (20 mg/kg, i.p.) in combination with disulfiram 
attenuated the changes observed in brain GABA, Glu, and DA levels. 
Administration of carbamathione (200 mg/kg, i.p.) in combination with NBI 
restored the changes observed in brain GABA, Glu, and DA levels as shown 
previously (figure 3.10). 
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5 IN VIVO MICRODIALYSIS AND UPLC-MS/MS FOR MONITORING 
A METABOLITE OF CARBMATHIONE 
5.1 Introduction 
In the previous chapters, capillary electrophoresis (CE) methods were used to 
detect brain gamma-amino butyric acid (GABA), glutamate (Glu), dopamine 
(DA) and carbamathione in microdialysis samples from the brain. In addition, a 
liquid chromatography-tandem mass spectrometric (LC-MS/MS) method was 
developed for the analysis of carbamathione in microdialysis samples from the 
plasma. These methods were used to elucidate carbamathione pharmacokinetics 
(PK) and pharmacodynamics (PD). It was demonstrated that both disulfiram and 
carbamathione administration led to changes in these brain neurotransmitters, but 
carbamathione led to a much greater change. However, carbamathione was 
cleared from the brain after 35 min and these changes in neurotransmitters 
continued for 2 h after carbamathione administration. One explanation for this 
was the possible formation of other metabolites of carbamathione with longer 
half-lives. This chapter describes an ultra-performance liquid chromatography-
tandem mass spectrometric (UPLC-MS/MS) method that was developed in the 
Williams, Stobaugh and Faiman laboratories (University of Kansas, Lawrence, 
KS). This method was originally developed to detect carbamathione in plasma 
samples that were precipitated by perchloric acid. During one of the studies 
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conducted, an unknown metabolite later identified as the N-acetyl cysteine (NAC) 
conjugate of carbamathione was discovered in the plasma samples. This UPLC-
MS/MS method was used to detect carbamathione and the NAC conjugate of 
carbamathione in microdialysis samples. 
 
5.1.1 Specific Aims of Research 
Figure 5.1 displays the structures of carbamathione and a NAC conjugate of 
carbamathione (S- methyl N, N-diethylthiocarbamate-N-acetyl cysteine [DETC-
NAC]). The goal of this research was to apply the previously developed UPLC-
MS/MS method to determine the concentration of carbamathione and DETC-
NAC in the nucleus accumbens and prefrontal cortex of a rat brain after the 
administration of disulfiram. Microdialysis samples from the plasma were also 
analyzed for these compounds. The purpose of this study was to determine 
whether DETC-NAC was detected in the brain after administration of disulfiram 
and to quantify the concentrations detected. Since this was an exploratory study, 
samples collection times were extended to 15 min and samples were collected for 
over 5 h.  
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Figure 5.1 Structures of carbamathione, DETC-NAC and diisopropyl carbamathione. 
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5.2 Experimental 
5.2.1 Chemicals and Reagents 
The chemicals and manufacturers were stated in Chapter 2, 3 and 4 (2.2.1, 3.2.1 & 
4.2.1 Chemicals and Reagents). Ringer’s solution was prepared as described in 
Chapter 3 (3.2.1 Chemicals and Reagents). Standard solutions of carbamathione 
were prepared as described in Chapter 3 (3.2.1 Chemicals and Reagents). DETC-
NAC and the internal standard (IS), diisopropyl carbamathione, were synthesized 
in the Stobaugh laboratory. The structure of the diisopropyl carbamathione is 
shown in figure 5.1. A stock solution of 1 mmol/L DETC-NAC (molecular weight 
[M.W.] 262 g/mol) and 1 mmol/L diisopropyl carbamathione were provided by 
the Stobaugh laboratory.  
 
5.2.2 UPLC-MS/MS Instrumentation 
The chromatographic separations were performed on an Phenomenex Kinetex C-
18 (50 mm x 2.1 mm i.d., 1.7 µm, 100 Ǻ) analytical column (Phenomenex, 
Torrance, CA, USA) at a flow rate of 0.4 mL/min with analysis time of 10 min. 
Solvents were delivered by a Waters Acquity UPLC system (Waters Corporation, 
Milford, MA, USA). Solvent A consisted of ultrapure water, methanol (MeOH), 
and formic acid (99:1:0.1, v/v/v). Solvent B consisted of MeOH, water and formic 
acid (99:1:0.1, v/v/v). The chromatograph consisted of a 6.5 min gradient 
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followed by a 1.5 min re-equilibration. The gradient used is given in table 5.2. A 
built-in diverter valve on the mass spectrometer was used to switch between waste 
and the mass spectrometer after 2 min. Tandem mass spectra were acquired on a 
Quattro Ultima “triple” quadrupole instrument (Micromass Ltd., Manchester, 
UK.). The probe capillary was optimized at 2.8 kV, and the desolvation and 
source temperatures were set to 250° C and 100° C, respectively. The cone gas 
flow rate was optimized at 49 L/h, and the desolvation and nebulizer gas flow rate 
was adjusted for maximum signal of analyte. Argon was used for collision-
induced dissociation and the cell vacuum was set at 2.23 × 10−3 mbar. 
Quadrupoles 1 and 3 were tuned to a resolution of 0.8 atomic mass units full 
width at half height. Selected reaction monitoring (SRM) parameters including 
precursor ions, product ions and collision energy are given in table 5.3. Mass 
spectrometric analysis was conducted in positive ion mode. Data processing was 
performed on MassLynx version 4.1 software. 
 
5.2.3 UPLC-MS/MS Method Development  
Diisopropyl carbamathione (IS) was synthesized since it was a non-endogenous 
glutathione adduct that was very similar in structure to carbamathione. 
Quantification of carbamathione and DETC-NAC was based on the ratio of the 
integrations of the SRM traces to the integration of the SRM trace from the IS.  
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Table 5.2 UPLC-MS/MS Gradient. 
 
Time (min) Solvent A Solvent B 
0.20 95.0% 5.0% 
4.50 47.7% 52.3% 
4.51 20.0% 80.0% 
6.50 20.0% 80.0% 
6.51 95.0% 5.0% 
8.00 95.0% 5.0% 
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Table 5.3 SRM parameters for the UPLC-MS/MS method. 
 
Analyte Precursor ion (m/z) 
Product ion 
(m/z) 
Cone voltage 
(V) 
Collision 
energy (V) 
DETC-NAC 263.0 100.0 25 15 
Carbamathione 407.1 100.1 35 30 
IS 435.0 128.0 35 30 
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The post-column infusion method was used to provide a qualitative assessment of 
matrix effects and to identify chromatographic regions most likely to experience 
matrix effects. Briefly, an infusion pump was used to deliver a constant amount of 
carbamathione and DETC-NAC into the liquid chromatography (LC) stream 
entering the ion source of the mass spectrometer. The mass spectrometer was run 
in SRM mode to follow the infused analytes. Blank dialysate was then injected on 
the LC column. Any endogenous compound that eluted from the column would 
cause a variation in electrospray ionization (ESI) response of carbamathione or 
DETC-NAC. The post-column infusion of 1 µmol/L carbamathione and 1 µmol/L 
DETC-NAC challenged by the injection of blank dialysate demonstrated no 
significant matrix interference. The comparison of standards prepared in Ringer’s 
and in water supported this assessment since there was no significant difference in 
the SRM peak areas. The selectivity of the method was tested by analyzing drug-
free plasma dialysate. Each dialysate sample was tested using the UPLC-MS/MS 
conditions described to ensure no interference with carbamathione and the IS. No 
other endogenous peaks were observed.  
 
5.2.4 Preparation of Standards and Calibration Curves 
DETC-NAC and carbamathione standards were prepared by serially diluting the 
stock solutions with Ringer’s solution. Calibration standards contained DETC-
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NAC and carbamathione prepared in concentrations of 1, 5, 10, 50, and 100 
nmol/L. Calibration plots were plotted as the ratio of the area of compound of 
interest to area of the internal standard versus concentration. Calibration curves 
were plotted every day (n = 5). 
 
5.2.5 Sample Preparation  
Twenty µL of standard solution or microdialysis sample was placed in an 
autosampler vial with a glass liner. Fifty nmol/L IS was prepared in 1% formic 
acid. Forty µL of this solution was added to the standard or microdialysis sample. 
The autosampler was set up to make 50 µL injections. 
 
5.2.6 Microdialysis 
5.2.6.1 Brain and Vascular Probes 
Brain microdialysis probes (CMA 12 Elite) with 2 mm membranes were 
purchased from CMA Microdialysis (North Chelmsford, MA, USA). The vascular 
probes were fabricated in-house as described in Chapter 3 (3.2.8.1 Brain and 
Vascular Probes). Delivery experiments were carried out by perfusing 1 µmol/L 
carbamathione and DETC-NAC through the microdialysis probes in vivo at 2 
µL/min, and determining the percentage that diffused through the membrane.   
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5.2.6.2 Animals and Surgery 
All awake experiments were carried out in accordance with Institutional Animal 
Care and Use Committee (IACUC) animal protocols as described in Chapter 2 
(2.2.6.2 Animals and Surgery). Sterile surgeries were conducted as described in 
Chapter 3 (3.2.8.2 Animals and Surgery). The initial anesthesia and preparation of 
the incision sites are described in detail in Chapter 2 (2.2.6.2 Animals and 
Surgery) and Chapter 3(3.2.8.2 Animals and Surgery).  
 
An intraperitoneal (i.p.) cannula was implanted into the abdomen the rat as 
described in Chapter 4 (4.2.5.2 Animals and Surgery). The i.p. cannula was 
externalized through a sterile incision in the neck. All incisions were closed with 
stitches or surgical staples. Microdialysis probes were implanted into the brain 
nucleus accumbens, brain prefrontal cortex and into the jugular vein as described 
in Chapter 3 (3.2.8.2 Animals and Surgery). After the surgical procedures, the rats 
were administered 0.5 to 3 mL/kg of saline subcutaneously (s.c.) and placed in a 
rat turn with a heating pad to facilitate recovery from anesthesia. 
 
5.2.6.3 Microdialysis Sample Collection 
Microdialysis samples were collected as described in Chapter 3 (3.2.8.3 
Microdialysis Sample Collection). After implantation, the brain probes and the 
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vascular probes were perfused with Ringer’s solution at 2 µL/min. The dead 
volume between the dialysis site and the fraction collector was also determined in 
order to accurately monitor the neurochemical changes as described in Chapter 3 
(3.2.8.3 Microdialysis Sample Collection). 
 
5.2.6.4 In Vivo Experiments 
The collection of 15 min samples was initiated after a 24 h waiting period for 
awake experiments. For dosing purposes, the disulfiram dose (200 mg/kg) was 
prepared as described in Chapter 4 (4.2.5.4 In Vivo Experiments). After the i.p. 
administration of disulfiram through the i.p. cannula, microdialysis samples were 
collected for six hours. At the end of the experiments, the rats were sacrificed by 
placement in an isofluorane chamber for approximately thirty minutes. Rat brains 
were harvested in order to perform a histological confirmation of brain probe 
position as described in Chapter 3 (3.3.4 Histological Confirmation of Brain 
Probe Position).1  
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5.3 Results and Discussion 
5.3.1 UPLC-MS/MS Calibration Results 
The carbamathione calibration curve was constructed by plotting the peak area 
ratio of carbamathione or DETC-NAC to the IS versus the concentration of 
carbamathione or DETC-NAC. The regression coefficient of the calibration 
showed good linearity (r2 = 0.9996 for carbamathione and r2 = 0.9997 for DETC-
NAC). Figure 5.4 displays representative calibration curves for DETC-NAC and 
carbamathione over a concentration range of 1-100 nmol/L.  
 
5.3.2 Microdialysis Probe Calibration 
The characteristics of the implanted microdialysis probes were evaluated at the 
end of each experiment. Based on the delivery experiments, the in vivo extraction 
efficiency by delivery (EEd) (mean ± standard error of mean [SEM], n = 3) for 
carbamathione was determined to be 24.3 ± 4.4% for the brain probes and 50.0 ± 
9.4% for the plasma vascular probes. Based on the delivery experiments, the in 
vivo EEd (mean ± SEM, n = 3) for DETC-NAC was determined to be 53.7 ± 9.8% 
for the brain probes and 81.3 ± 10.8% for the plasma vascular probes.  
 
 
 
 219 
Figure 5.4 Representative calibration curves for UPLC-MS/MS method. 
 
 
 
 
 220 
5.3.3 In Vivo Studies 
Figure 5.5 shows the concentration in plasma microdialysis samples versus time 
profile for carbamathione and DETC-NAC after the i.p. administration of 
disulfiram (200 mg/kg, n = 3). Figure 5.6 shows the concentration in the brain 
nucleus accumbens microdialysis samples versus time profile for carbamathione 
and DETC-NAC after the i.p. administration of disulfiram (200 mg/kg, n = 3). 
Figure 5.7 shows the concentration in the brain prefrontal cortex microdialysis 
samples versus time profile for carbamathione and DETC-NAC after the i.p. 
administration of disulfiram (200 mg/kg, n = 3).  
 
Carbamathione and DETC-NAC appear to have similar distribution curves in the 
plasma. Carbamathione had a Cmax of 148.4 ± 41.1 nmol/L at 285 min after 
disulfiram administration. DETC-NAC had a Cmax of 86.7 ± 14.2 nmol/L at 300 
min after disulfiram administration. This indicated that DETC-NAC was still 
increasing in concentration at the last collection and had not reached its true Cmax. 
The area under the dialysate concentration versus time profile (AUC) for 
carbamathione in the brain nucleus accumbens, brain prefrontal cortex and plasma 
after the administration of disulfiram (200 mg/kg i.p.) were 1.75 ± 0.83 µmol/L 
min, 2.20 ± 1.82 µmol/L min and 31.8 ± 14.9 µmol/L min. 
 
 
 221 
Figure 5.5 Carbamathione and DETC-NAC concentration versus time profile after 
200 mg/kg dose of disulfiram and 15 min sampling interval in plasma dialysate.  
Concentrations of carbamathione and DETC-NAC in rat plasma following disulfiram 
administration (200 mg/kg i.p., n = 3). Microdialysis samples were collected every 15 min. Data 
shown as concentration (mean ± SEM).  
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Figure 5.6 Carbamathione and DETC-NAC concentration versus time profile after 
200 mg/kg dose of disulfiram and 15 min sampling interval in brain dialysate.  
Concentrations of carbamathione and DETC-NAC in rat brain nucleus accumbens following 
disulfiram administration (200 mg/kg i.p., n = 3). Microdialysis samples were collected every 15 
min. Data shown as concentration (mean ± SEM).  
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Figure 5.7 Carbamathione and DETC-NAC concentration versus time profile after 
200 mg/kg dose of disulfiram and 15 min sampling interval in brain dialysate.  
Concentrations of carbamathione and DETC-NAC in rat brain prefrontal cortex following 
disulfiram administration (200 mg/kg i.p., n = 3). Microdialysis samples were collected every 15 
min. Data shown as concentration (mean ± SEM).  
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The AUC for carbamathione concentrations in the brain nucleus accumbens, brain 
prefrontal cortex and plasma after carbamathione administration (200 mg/kg i.v.) 
were 270 ± 67 µmol/L min, 273 ± 66 µmol/L min  and 1854 ± 458 µmol/L min, 
respectively (see table 3.21).  As described in Chapter 4, a 200 mg/kg dose of 
carbamathione and a 200 mg/kg dose of disulfiram are approximately equimolar 
(4.3.2.1.1 Administration of Disulfiram). The percent conversion of disulfiram to 
carbamathione was determined to be less than 2%. This was similar to the value 
obtained in the study described in Chapter 4 (<1%, 4.3.2.1.1 Administration of 
Disulfiram). 
 
The concentrations of carbamathione and DETC-NAC in the brain nucleus 
accumbens and prefrontal cortex had profiles similar to those in the plasma. In the 
brain nucleus accumbens, carbamathione had a Cmax of 8.3 ± 4.4 nmol/L at 300 
min after disulfiram administration. DETC-NAC had a Cmax of 3.4 ± 1.5 nmol/L at 
300 min after disulfiram administration. In the brain prefrontal cortex, 
carbamathione had a Cmax of 10.1 ± 8.5 nmol/L at 210 min after disulfiram 
administration. DETC-NAC had a Cmax of 6.1 ± 4.6 nmol/L at 330 min after 
disulfiram administration. The time profile curves indicated that DETC-NAC was 
still increasing in concentration at the last collection and had not reached its true 
Cmax in the brain. The AUC for DETC-NAC in the brain nucleus accumbens, 
brain prefrontal cortex and plasma after the administration of disulfiram (200 
 225 
mg/kg i.p.) were 614 ± 263 nmol/L min, 1.05 ± 0.83 µmol/L min and 17.6 ± 5.9 
µmol/L min.  
 
5.4 Discussion 
DETC-NAC is a metabolite that is formed after the formation of carbamathione 
since it is the glutathione side-chain that is modified (see figure 5.1). The results 
from this study showed that DETC-NAC appeared in the plasma, the brain 
nucleus accumbens and the brain prefrontal cortex after the administration of 
disulfiram. The elimination of disulfiram and its numerous metabolites is a very 
slow process.2-5 This may explain the slow continuous increase in carbamathione 
and DETC-NAC in plasma over time. The concentrations of carbamathione and 
DETC-NAC in the plasma and the brain followed very similar time profiles. 
However, the concentration of carbamathione in the brain showed more variation 
than the concentration of DETC-NAC. This may be because carbamathione is the 
first metabolite formed by the carbamoylation of glutathione and appears to form 
peripherally before crossing the blood-brain barrier (BBB). Reactive metabolites 
formed from the biotransformation of drugs are normally detoxified by 
conjugating with glutathione followed by mercapturic acid metabolism to produce 
their respective NAC conjugates.6 Since NAC conjugates are normally excreted, 
DETC-NAC may be one of the last steps in the metabolism of disulfiram. The 
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discovery of a NAC metabolite of carbamathione in the brain has many 
implications for this project. The discovery of DETC-NAC in the brain suggests 
that the study of other intermediates that may also cross the BBB is warranted. 
The formation of DETC-NAC and its slow distribution in the brain may help 
explain the prolonged effects of carbamathione administration on brain 
neurotransmitters even after carbamathione has been cleared from the brain.  
 
5.5 Conclusions 
The work in this chapter showed the application of a UPLC-MS/MS method for 
the simultaneous detection of carbamathione and a metabolite of carbamathione in 
rat brain nucleus accumbens, brain prefrontal cortex and plasma dialysate. The 
analytical method exhibited good linearity, reproducibility, and selectivity. Both 
carbamathione and the metabolite, DETC-NAC were detected in the brain after 
the administration of disulfiram. However, this study did not elucidate whether 
DETC-NAC crossed the BBB or carbamathione was required to cross the BBB to 
form DETC-NAC. Future studies with DETC-NAC can help illuminate its role, if 
any, in the effect on brain neurotransmitters observed after both carbamathione 
and disulfiram administration. Such studies include the investigation of brain 
neurotransmitters after the administration of DETC-NAC.  
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6 CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Summary of Dissertation 
6.1.1 CE-LIF Method for GABA, Glu, and Carbamathione in Microdialysis 
Samples 
A capillary electrophoresis (CE-LIF) method was developed for the simultaneous 
detection of gamma-amino butyric acid (GABA), glutamate (Glu) and 
carbamathione in microdialysis samples from the brain nucleus accumbens. 
Microdialysis samples were derivatized with napthalene-2,3-dicarboxyaldehyde  
(NDA) since it was not fluorescent itself and it reacted rapidly to give stable 
fluorescent cyanobenzo[f]isoindol (CBI) derivatives. The derivatization of the 
primary amine provided the added advantage of including carbamathione in the 
analysis of a sample since it is also a primary amine. The limits if detection 
(LOD) for GABA, Glu and carbamathione were 1.0 x 10-8, 6.0 x 10-9, and 1.5 x 
10-8 mol/L respectively. These LOD were sufficient for detecting GABA, Glu, 
and carbamathione in the rat brain. A temporal resolution of 5 min was achieved 
for this method. 
 
The effect of the intravenous (i.v.) administration of carbamathione (200 mg/kg 
i.v.) on GABA and Glu levels in the brain nucleus accumbens was evaluated. 
Administration of carbamathione was correlated to changes in GABA and Glu in 
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both anesthetized and awake rats. In anesthetized rats, basal GABA levels were 
significantly reduced and basal Glu levels were significantly increased after the 
administration of carbamathione. In awake rats, basal GABA levels were 
significantly reduced whereas basal Glu levels were initially increased and 
eventually decreased below basal concentrations. The effect of carbamathione on 
basal Glu levels of the awake rats may be explained by carbamathione being a 
partial N-methyl-D-aspartic acid (NMDA) antagonist. The role of carbamathione 
as a partial NMDA antagonist may be important since NMDA antagonists have 
been shown to be effective in treating alcohol dependence and blocking cocaine-
induced behavior.1-3  
 
Ketamine which is also a known NMDA antagonist, was used and may be 
responsible for the differences observed in Glu levels between anesthetized and 
awake rats. Several studies with ketamine suggest that ketamine alters the 
response of NMDA receptors to drug administration. 4-6 The anesthesia also had 
an impact on the pharmacokinetics (PK) of carbamathione clearance from the 
brain. The elimination rate constant, Kelim was determined to be 0.13 ± 0.01 min-1 
for anesthetized rats and 0.16 ± 0.02 min-1 for awake rats. The slower PK for the 
anesthetized rats was expected since the anesthesia is known to slow down the 
basal metabolic rate.  
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These studies showed that carbamathione administration had an effect of GABA 
and Glu levels in the nucleus accumbens of the rat brain. Future studies will focus 
on the addition of dopamine (DA) to the analysis because DA has been shown to 
be one of the neurotransmitters involved in the pathways associated with 
addiction.7,8 Future studies will also focus on adding the determination of 
carbamathione concentrations in plasma dialysate to the analysis. This would 
provide additional information on the PK and pharmacodynamics (PD) of 
carbamathione. 
 
6.1.2 MEKC-LIF Method for GABA, Glu, DA, and Carbamathione in 
Microdialysis Samples 
A micellar electrokinetic chromatography coupled with laser-induced 
fluorescence (MEKC-LIF) method was developed by modifying an existing 
method for the simultaneous detection of GABA, Glu, DA, and carbamathione in 
microdialysis samples from the brain.9 Similar to the CE-LIF method in Chapter 
2, microdialysis samples were derivatized with NDA. The LOD for GABA, Glu, 
DA and carbamathione were 1.5 x 10-9, 6.0 x 10-10, 5.0 x 10-10 and 1.0 x 10-9 
mol/L respectively. In addition, a previously developed liquid chromatography-
tandem mass spectrometric (LC-MS/MS) method was utilized to determine 
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carbamathione concentrations in plasma dialysate.23 The LOD for this method 
was 2.5 x 10-10 mol/L.  
 
These methods were initially used to evaluate the effect of carbamathione 
administration (200 mg/kg i.v.) on GABA, Glu, and DA levels in the nucleus 
accumbens and prefrontal cortex of rat brain. A temporal resolution of 5 min was 
achieved for this method. The half-lives of carbamathione in the plasma, 
prefrontal cortex and nucleus accumbens were determined to be 4.81 ± 0.97, 4.31 
± 0.59 and 4.19 ± 0.66 min respectively. Thus the sample collection time of 5 min 
was more than the estimated half-lives of carbamathione. The sample collection 
time was reduced to 3 min in order to obtain important PK and PD data. However, 
the values obtained for the elimination constants by 3 min sampling were very 
close to those obtained by 5 min sampling. This suggested that 5 min sampling 
was sufficient to obtain the relevant PK and PD data for carbamathione. 
 
Administration of carbamathione was correlated with an initial increase in 
extracellular Glu concentration and a subsequent decrease after 30 min. This 
increase and decrease may possible be correlated with the PK of carbamathione in 
the brain, which suggests that the initial increase may be due to carbamathione 
acting as a partial NMDA antagonist. Administration of carbamathione was 
correlated with an increase in DA levels in the brain and this increase was more 
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pronounced in the nucleus accumbens than in the prefrontal cortex. This was 
expected since carbamathione also appeared to decrease GABA in the prefrontal 
cortex, which usually inhibits DA in the nucleus accumbens. Administration of 
carbamathione was also correlated with a decrease in extracellular GABA levels 
in the brain with a greater decrease occurring in the prefrontal cortex than in the 
nucleus accumbens. These changes in GABA, Glu and DA also appeared to be 
dose-dependent since three doses were evaluated (200, 50, and 20 mg/kg).  
 
These studies demonstrated that carbamathione administration was correlated 
with changes in brain GABA, Glu, and DA levels. This effect of carbamathione 
may explain the anti-craving property of disulfiram observed in clinical trials for 
the treatment of alcohol and cocaine addiction.10,11 However, the mechanism by 
which carbamathione administration affects the brain neurotransmitters remains 
unknown. Future studies will focus on elucidating this mechanism in by 
selectively inhibiting disulfiram metabolism and investigating whether changes in 
brain neurotransmitters were observed. 
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6.1.3 Laboratory-Built MEKC-LIF Method for GABA, Glu, DA, and 
Carbamathione in Microdialysis Samples 
A laboratory-built MEKC-LIF method was developed by modifying an existing 
method for the simultaneous detection of GABA, Glu, DA, and carbamathione in 
microdialysis samples from the brain nucleus accumbens.9 The LOD for GABA, 
Glu, DA, and carbamathione were 6.0 x 10-9, 1.0 x 10-8, 5.0 x 10-9 and 1.0 x 10-8 
mol/L respectively. In addition, the LC-MS/MS method described in Chapter 3 
was used to determine carbamathione concentrations in plasma dialysate.23 A 
temporal resolution of 5 min was achieved since the study described in Chapter 3 
determined this resolution to be sufficient. 
 
The goal of this study was to utilize the MEKC-LIF method to determine the 
changes in rat brain GABA, Glu, and DA levels as related to the intraperitoneal 
(i.p.) administration of disulfiram (200 mg/kg i.p.) and an inhibitor of disulfiram 
metabolism (N-benzylimidazole [NBI], 20 mg/kg i.p.). These studies 
demonstrated that carbamathione was detected in the brain after disulfiram 
administration but was not detected when NBI was administered. Disulfiram also 
appeared to be correlated with changes in brain neurotransmitters, albeit to a 
much lesser degree than carbamathione administration (as observed in Chapter 3). 
When NBI was administered with disulfiram, no statistically significant changes 
in brain neurotransmitters were observed. However, administration of 
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carbamathione (200 mg/kg i.p.) in combination with NBI restored the changes 
observed in brain neurotransmitters. This suggested that NBI did not interfere 
with the mechanism by which carbamathione administration had an effect on 
brain neurotransmitters. This was an important study since it demonstrated that 
the formation of carbamathione was necessary to observe changes in the brain 
neurotransmitters after both carbamathione and disulfiram administration.   
  
6.1.4  UPLC-MS/MS Method for Carbamathione and a Metabolite of 
Carbamathione in Microdialysis Samples 
Chapter 5 described an ultra-performance liquid chromatography-tandem mass 
spectrometric (UPLC-MS/MS) method that was originally developed in the 
Williams, Stobaugh and Faiman laboratories (University of Kansas, Lawrence, 
KS) to detect carbamathione in plasma samples that were precipitated by 
perchloric acid. During one of these studies, an N-acetyl cysteine (NAC) 
conjugate of carbamathione (S- methyl N, N-diethylthiocarbamate-N-acetyl 
cysteine [DETC-NAC]) was discovered in the plasma samples. This UPLC-
MS/MS method was used to determine DETC-NAC and carbamathione in 
microdialysis samples from the plasma, brain nucleus accumbens, and brain 
prefrontal cortex after the administration of disulfiram (200 mg/kg i.p.). Samples 
were collected every 15 min for over 5 h.  
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This study demonstrated that DETC-NAC and carbamathione were detected in the 
plasma, brain nucleus accumbens and brain prefrontal cortex of awake rats after 
the administration of disulfiram (200 mg/kg i.p.). This was an exploratory study 
to determine the existence of a metabolite other than carbamathione in the rat 
brain after disulfiram administration.  This study suggested that there may be 
other metabolites of disulfiram that either cross the blood-brain barrier (BBB) or 
are formed in the brain. This study did not demonstrate whether DETC-NAC, 
carbamathione or both crossed the BBB. This study suggested that the formation 
of DETC-NAC and its slow distribution in the brain may help explain the 
prolonged effects of carbamathione administration on brain neurotransmitters 
even after carbamathione has been cleared from the brain. Future studies will 
focus on the exploration of other metabolites of disulfiram that may appear in the 
brain after the administration of disulfiram. Another important study would be the 
investigation of the effect, if any, of DETC-NAC administration on these brain 
neurotransmitters. 
 
6.2 Future Directions 
The research discussed in this dissertation has many implications for the treatment 
of alcohol and cocaine addiction. Disulfiram is a drug that has been used for over 
60 years in the treatment of alcoholism and has recently been found to be 
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efficacious in the treatment of cocaine addiction.11-14 It is important to note that in 
the cocaine trial, disulfiram efficacy was independent of its effect as an alcohol 
aversive agent since disulfiram appeared to be more effective when the patients 
were not alcoholic.14 These studies and the work in this dissertation suggest that 
disulfiram has an effect in the brain that is independent of its effect on aldehyde 
dehydrogenase (ALDH2). The fact that carbamathione, a metabolite of disulfiram 
produced a change in the brain neurotransmitters suggest that disulfiram may 
have a centrally mediated effect. Several studies could be conducted to help 
elucidate the role of carbamathione as a pharmacological agent in alcohol and 
cocaine studies. The analytical methods developed in this dissertation can be used 
to analyze the samples generated by such studies. 
 
One important study would be the investigation of the effect of administering 
cocaine or alcohol followed by carbamathione on the brain neurotransmitters. 
This study would help elucidate whether carbamathione could change or even 
reverse the effect of cocaine or alcohol.  All the studies in this dissertation 
involved a single bolus dose of carbamathione or disulfiram. Thus another 
interesting experiment would be the investigation of the effect of multiple dosing 
schemes using carbamathione. This study would demonstrate whether the changes 
in neurotransmitter levels were reversible. This study would also elucidate 
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whether multiple doses of carbamathione would produce a greater degree of 
change in the neurotransmitters than a single dose.  
 
Another significant study would involve the study of a behavioral model for 
alcohol and cocaine addiction. Animal models of drug addiction can provide a 
means of studying both the behavioral and biological basis of drug addiction. The 
neurobiological mechanisms involved in the positive reinforcing effects of drugs 
and the negative reinforcing effects of drug abstinence have been elucidated in 
several models.15-18 The effects of pharmacological interventions such as 
carbamathione administration can be studied using animal models. Studies with 
such models would also help elucidate the difference in basal neurotransmitters 
levels between the addicted and normal animal. In addition, information on the 
effect of pharmacological interventions on these neurotransmitter levels can also 
be obtained. 
 
In addition to studies into the pharmacology of carbamathione, it would be 
relevant to explore other metabolites of carbamathione (such as DETC-NAC) and 
study their effects on important brain neurotransmitters.  Metabolite profiling is 
an important part of the drug discovery and development process. Mass 
spectrometry is a useful tool in facilitating the identification of previously 
uncharacterized metabolites, especially when combined with wet chemistry 
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techniques like nuclear magnetic resonance (NMR) and chemical 
derivatization.19-22 As the metabolites are identified, studies into which of the 
metabolites cross the BBB would also be significant. 
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